

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 35/20, 35/55, 39/00, 39/395, G01N 33/53, C07K 14/435, 16/18, 16/30, C12N 15/12, 15/62	A1	(11) International Publication Number: WO 95/15171 (43) International Publication Date: 8 June 1995 (08.06.95)
(21) International Application Number: PCT/US94/13967 (22) International Filing Date: 5 December 1994 (05.12.94) (30) Priority Data: 08/162,402 3 December 1993 (03.12.93) US (71) Applicant: CANCER RESEARCH FUND OF CONTRA COSTA [US/US]; 2055 North Broadway, Walnut Creek, CA 94586 (US). (72) Inventors: PETERSON, Jerry, A.; 1089 Via Roble, Lafayette, CA 94549 (US). CERIANI, Roberto, L.; 1989 Via Roble, Lafayette, CA 94549 (US). LAROCCA, David, J.; 1530 Calle Tulipanes, Encinitas, CA 92024 (US). (74) Agent: AMZEL, Viviana; Ratner & Prestia, 500 North Gulph Road, P.O. Box 980, Valley Forge, PA 19482 (US).		(81) Designated States: CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: A 46 Kd HUMAN MILK FAT GLOBULE ANTIGEN (57) Abstract <p>A polypeptide has the antibody binding activity of the 46 Kdalton HMFG antigen and/or homology to at least one of the light chains of clotting factors V and VIII and/or contains RGD and/or EGF-like segments. The polypeptide is provided as a recombinant and/or glycosylated and/or fusion protein. An antibody has high affinity for specificity epitopes of the polypeptide of the invention. Polynucleotide segments encode the polypeptide, recombinant and fusion protein of the invention or fragments thereof, and immunoassay kits comprise the antibodies and/or polypeptides of the invention and other components. In vivo, ex vivo, and in vitro methods of therapy, vaccination and diagnosis utilize the polypeptide, fusion protein anti-sense nucleotides, antibodies and/or polynucleotides of the invention.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A 46 Kd Human Milk Fat Globule Antigen

5

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to the field of diagnosis and therapy of cancer and the prevention and treatment of viral infections. More particularly, it relates to a polypeptide having the antibody binding specificity of the 46 Kdalton HMFG antigen, hybrid protein thereof, anti-idiotypic antibodies and polynucleotides, anti-sense polynucleotides encoding them, kits, and their application to the in vitro detection, the in vivo and ex vivo of delivery of a therapeutic agent, the detection of the polynucleotides by hybridization with labeled probes, and the vaccination against and treatment of cancer and viral infections.

15 Description of the Background

The human milk fat globule (HMFG) has been used extensively as a source of antigenic material for the preparation of both polyclonal and monoclonal antibodies that have found widespread use in the diagnosis of breast cancer, as well as in the study of the breast epithelial cell surface and the processing of its antigenic components.

20 Polyclonal antiserum was originally prepared, that after appropriate absorptions with non-breast tissue was found to identify surface antigens of human mammary epithelial cells (HME-Ags). This antiserum (anti-HME) had a high specificity for normal breast epithelial cells and breast carcinomas. It identified mainly three components of the human milk fat globule which had molecular weights of 150 Kdalton, 70 Kdalton, 25 and 46 Kdalton, respectively.

Monoclonal antibodies were first made against the HMFG in 1980. These antibodies were applied to identify a hitherto unknown component of the breast epithelial cell surface, a large molecular weight mucin-like glycoprotein, that was named non-penetrating glycoprotein (NPGP). This latter component appears to be 30 extremely antigenic in the mouse. The vast majority of monoclonal antibodies prepared against HMFG as well as breast tumors have been found to have specificity against different epitopes of this mucin. Less frequently, monoclonal antibodies have been prepared against the 70 Kdalton and 46 Kdalton components of the HMFG.

The reason for the high immunogenicity of NPGP was elucidated by the 35 characterization of cDNA clones selected from a λ gt11 breast cell library using both polyclonal and monoclonal antibodies against the mucin. These cDNA clones consist

of large arrays of highly conserved 60 bp tandem repeats. The resulting 20 amino acid repeat contains epitopes for several anti-mucin antibodies. The repeat is apparently unstable at the genomic level. This may account for the observed polymorphism seen at the gene, RNA and protein levels for this high molecular weight mucin. An initial
5 report on cDNA cloning of the mucin product suggested that the core protein had a molecular weight of about 68 Kdalton. However, the mRNA was found to be large enough to code for proteins from about 170 Kdalton to 230 Kdalton. More recently, using milder deglycosylation methods, a core protein was identified having a molecular weight of about 200 Kdalton. Attention has also been devoted to the study and use
10 of the NPGP mucin, largely as a result of its high immunogenicity. Thus, a large number of monoclonal antibodies were prepared against it. However, the smaller components of HMFG also appear to be important molecules on the surface of breast epithelial cells. They have a breast specificity as demonstrated by the anti-HMFG antibodies.

15 The 46 Kdalton and 70 Kdalton HMFG antigens are found in serum of breast cancer patients and thus can be used as markers for breast cancer in serum assays. In addition, the 70 Kdalton component has been found to co-purify with the intact mucin complex and has been reported to be associated with the NPGP mucin complex by means of disulfide bonds, making it a possible linker protein of this surface mucin
20 complex. Polyclonal antibodies against a major component of the HMFG having molecular weight of 155 Kdaltons have been prepared. It was found that antisera bound also to the apical surface of lobules and terminal ducts, but not to the larger ducts of the mammary gland. The latter also did not bind to the apical surface of normal apocrine and eccrine sweat gland coils and ducts, or sebaceous glands in skin.
25 The HMFG-GPI55 did become localized in Paget's disease and breast disease but not in cases of extramammary disease.

Few monoclonal antibodies, however, have been prepared against the smaller components of the HMFG system, such as the 70 Kdalton and 46 Kdalton HMFG antigens. The breast mucin glycoprotein molecule appears to be highly antigenic
30 because of its internally repeated structure. The components of the mucin glycoprotein was recently determined and a partial sequence for the 70 Kdalton antigen obtained by cDNA cloning. A role for the 70 Kdalton antigen has been suggested as a linker protein for the breast mucin. The 46 Kdalton component of the HMFG system has been found to be present in the serum of breast cancer patients. In addition, with the
35 aid of both monoclonal and polyclonal antibodies against the 46 Kdalton HMFG antigen, circulating immune complexes of the 46 Kdalton HMFG antigen were detected in breast

cancer patients, and an increase in the circulating 46 Kdalton HMFG antigen was found to be associated with tumor burden.

Accordingly, there is still a need for an improved product and methods suitable for diagnostic and therapeutic applications to human cancer and virus-associated
5 infections.

SUMMARY OF THE INVENTION

This invention relates to a pure, isolated polypeptide having the antibody binding specificity of the 46 Kdalton HMFG antigen and/or homology to at least a portion of a light chain of clotting factors V and VIII, and/or RGD and/or EGF-like segments, and
10 to a composition comprising the polypeptide and a biologically acceptable carrier, e.g. a pharmaceutically-acceptable carrier. The naked polypeptide may be produced by recombinant cloning and expression in prokaryotes and the glycosylated version in eukaryotes. The polypeptide of the invention is also provided, with a second antigenic polypeptide bound thereto, as a fusion protein and as a composition comprising the
15 hybrid protein and a biologically acceptable carrier, e.g. a pharmaceutically-acceptable carrier. An antibody detecting kit provided comprises, in separate containers, the polypeptide of the invention or a functional fragment thereof, anti-constant region immunoglobulin or protein G or A or fragments thereof, and instructions for its use. Another kit comprises, in separate containers, the fusion protein of the invention
20 comprising a second antigenic polypeptide, or an anti-second polypeptide polyclonal or monoclonal antibody, and anti-constant region immunoglobulin, protein G or A or binding fragments thereof. The polypeptide of this invention or a binding fragment thereof may also be applied to the vaccination of a mammal such as a human in an amount and under conditions effective to raise antibodies which are capable of
25 selectively binding to the 46 Kdalton HMFG antigen, functional fragments, or cells carrying them. Yet another application for the polypeptide of the invention is in the in vitro detection of circulating anti-46 Kdalton HMFG antigen antibody. This can be attained by adding the polypeptide of the invention or a functional fragment thereof to a sample under conditions effective to form an antibody-polypeptide complex, and
30 determining the presence of any complex formed. The polypeptide of this invention or a functional fragment thereof is also useful for the therapeutic treatment of viral infections such as those associated with the HIV and rotavirus, among others. This may be attained by, e.g. feeding a subject the polypeptide of the invention or a functional fragment thereof in an amount and under conditions effective to treat or
35 prevent the viral infection. The polypeptide may be utilized as such or in glycosylated

form. Another way of detecting the presence of circulating anti-46 Kdalton HMFG antigen antibody is by contacting a sample with the fusion protein of this invention to form an antibody-fusion protein complex, then adding an anti-second polypeptide antibody to form a double antibody-fusion protein complex, and determining the
5 presence of any double antibody complex formed. The assay may be a solid-phase assay, e.g. where the fusion protein is attached to a solid support.

Still part of this invention are antibodies having high selectivity, affinity and specificity for the 46 Kdalton HMFG antigen, and as anti-idiotypic antibodies, and to a composition comprising the antibodies and a biologically acceptable carrier, e.g. a
10 pharmaceutically-acceptable carrier. The antibodies are also provided as an immunoassay kit that comprises, in addition, in separate containers, the monoclonal antibody having high affinity, selectivity and specificity for the 46 Kdalton HMFG antigen or a functional fragment thereof, an anti-constant region immunoglobulin or protein G or A or fragments thereof, and instructions for its use. Also encompassed
15 by this invention is an anti-cancer kit comprising, in separate containers, a monoclonal antibody having specificity for the 46 Kdalton HMFG antigen, and an anti-cancer therapeutic agent selected from the group consisting of immunotoxins and radionucleides, among others. The antibodies selectively binding the 46 Kdalton HMFG antigen are useful for detecting the presence of cancer cells, the polypeptide or
20 fragments thereof in a biological sample such as milk, serum and the like. They may be added to a biological sample of cancerous origin to form an antibody-polypeptide complex, and then determining the presence of any complex formed. The antibodies may also be applied to determining the presence of circulating epithelial cells in a biological sample by adding them to the sample under conditions effective to form an
25 antibody-cell polypeptide complex, and determining the presence of any complex formed. Cells that express the polypeptide of the invention or fragments thereof may be imaged by administering to a subject suspected of being afflicted with cancer or under cancer therapy the anti-46 Kdalton antibody of the invention under conditions effective to deliver it to target body cells expressing the 46 Kdalton HMFG antigen or
30 fragments thereof to form an antibody-cellular antigen complex, then administering to the subject a detectable labeled molecule capable of binding to the antibody at a site other than its binding site for the cellular antigen, and non-invasively detecting the presence of label in the subject's body associated with any complex formed.

This invention also relates to polynucleotides encoding the polypeptide described
35 herein or antibody binding fragments thereof as well as polynucleotides encoding the fusion protein of the invention or antibody binding fragments thereof, DNA segments

which are complementary to the polynucleotides provided herein, and hybrid polynucleotides, hybrid vectors and host cells transfected with the vectors. The DNA and RNA segments of the invention may be used for the production of the polypeptides and in a method of detecting the presence of a polynucleotide segment encoding the polypeptide described above or fragments thereof by hybridization under pre-set conditions. A group of polynucleotides comprising an anti-sense segment to a polynucleotide encoding the polypeptide of the invention or antibody binding fragments thereof of about 15 to 3000 bases. These polynucleotides are suitable for treating breast cancer by their administration to a patient therapeutic amount. A therapeutic agent may be delivered in vivo to target cells expressing the 46 Kdalton HMFG antigen or a functional fragment thereof by administering it to a subject suspected of carrying target cells, such as malignant tumor cells, in a therapeutic amount operatively linked to the anti-46 Kdalton HMFG antigen antibody at a site other than the antigen's binding site under conditions effective for reaching the target cells environment, and allowing the antibody to bind to the cells and the therapeutic agent to act upon the cells. A therapeutic agent may also be delivered ex vivo to target cells expressing the 46 Kdalton HMFG antigen or a functional fragment thereof by, contacting the anti-46 Kdalton HMFG antigen antibody carrying the therapeutic agent with a sample containing the target cells, such as cancer cells under conditions effective to promote the formation of antibody-cell polypeptide complexes, separating any complexes formed, and returning the sample to the subject.

A more complete appreciation of the invention and many of the intended advantages thereof will be readily perceived as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the expression of BA46-1 specific mRNA in human carcinoma cell lines. Total RNA (20 μ g/lane) was run on a 1.4% agarose gel, blotted, and hybridized to 32 P labelled RNA generated from the BA46-1 cDNA clone. The contents of the samples in the different lanes are as follows: a) A549 (lung); b) BT20 (breast); c) ELLG (breast); d) Raji (lymphoid); e) SKBR3 (breast); f) SKOV3 (ovary); g) MDA-MB-361 (breast); h) MDA-MB-331 (breast); i) HeLa (cervix); j) HS578T (breast); k) HT29 (colon); l) PanCI (pancreas); m) MCF7 (breast). Exposure was 16 hours with an intensifying screen.

10 Figure 2 shows a dendrogram of the aligned C-type domains for various related proteins.

Other objects, advantages and features of the present invention will become apparent to those skilled in the art from the following discussion.

BEST MODE FOR CARRYING OUT THE INVENTION

15 This invention arose from a desire by the inventors to improve on technology useful for the detection, diagnosis, and treatment of breast cancer of epithelial origin and/or prevent viral infections. Monoclonal antibodies against the 46 Kdalton HMFG antigen have also shown some effectiveness in the radioimmunotherapy of transplanted human breast tumors in experimental animals nude mice. Moreover, an impure preparation of the 46 Kdalton HMFG antigen also been implicated in the inhibition of viruses, such as rotaviruses which are infectious agents causing gastroenteritis, particularly affecting infants, young children and immunologically compromised patients. This work relies on the isolation of cDNA clones that encode partial DNA sequences of the 46 Kdalton apparent molecular weight (app. MW) polypeptide component of the HMFG system and of monoclonal antibodies that bind the 46 Kdalton component of the human milk fat globule (HMFG) system with high affinity and selectivity. The HMFG membrane system, in fact, truly represents a purified portion of the apical surface of the normal breast epithelial cell. The 46 Kdalton app. MW component is a major molecular species of the HMFG membrane and represents a major and important component of the apical surface of the normal breast epithelial cell. Nucleotide and deduced amino acid sequences of a partial cDNA fragment obtained first are shown in Table 1 of Example 7 below. The partial amino acid sequence of the encoded polypeptide is about 217 amino acids long, has a theoretical MW of about 25 Kdaltons and represents the C-terminus of the 46 Kdalton

HMFG antigen. This fragment contains four potential sites for N-linked glycosylation and is asparagine and leucine rich. Starting from the C-terminus, the nucleotide sequence extends to the 3' end of the mRNA which contains the AATATA consensus sequence preceding the poly-A segment for cleavage and polyadenylation. A comparison of the C-terminal nucleotide sequence to sequences in the EMBL database using FSTNSCAN (PCGENE) revealed extensive homology with human serum factors V and VIII, and with protein C. The C-terminal deduced protein sequence, however, shares identity only with factors V and VIII but not with protein C since the homology at the nucleotide level is found in an intervening sequence (See, Table 2 below). There is also an about 43% identity to factor V and about 38% identity to factor VIII. The regions of factors V and VIII shown in Table 2 share an about 47% identity with the fragment of the protein shown. The results of the analysis of the deduced amino acid sequence of the C-terminal 46 Kdalton antigen fragment are consistent with it being a glycosylated protein. Its homology to clotting factors V and VIII may be found in the C1C2 region of the light chain of factor VIII. Human antibodies that bind this region of the light chain of factor VIII inhibit the factor by preventing its interaction with phospholipids, and since this region of factor VIII has been implicated in phospholipid binding, it is likely that the homologous region in the C-terminus of the 46 Kdalton HMFG polypeptide serves a similar role. The appearance of a shared domain in otherwise different proteins may be due to exon shuffling. The C-terminus of the 46 Kdalton HMFG antigen may serve as a novel "anchor" sequence for the 46 Kdalton HMFG protein or it may be involved in the binding of mucin and/or cell membranes to the phospholipids found on the surface of growing milk fat droplets. Alternatively, the homologous sequence may be involved in the assembly of the mucin complex at the plasma membrane surface.

The single stranded RNA probe provided herein is complementary to the ORF found in the cDNA insert, that is in frame with the β -galactosidase DNA sequence in the λ gt11 vector. This ORF, therefore, represents the sense strand of the C-terminal portion of the gene since only the complementary strand probe binds to a specific 2.2 kilobase mRNA of epithelial cell lines. The cDNA sequence encoding the C-terminus of the 46 Kdalton HMFG glycoprotein was reported in the original text of this patent, and its deduced amino acid sequence showed to have extensive sequence similarity with the C1C2 domain of human coagulation factors V and VIII (43% and 38% respectively). Upon further searching, other proteins were found that have sequences similar to the C1C2 domain of factors V and VIII. These include a neuronal recognition molecule (A5 antigen) of *Xenopus* (Takagi et al, *Neuron* 7:295 (1991)), discoidin I of

Dictyostelium discoideum (Poole et al, PNAS (USA) 90:5677 (1993)), a receptor tyrosine kinase with an extracellular discoidin I-like domain (Johnson et al, PNAS (USA) 90:5677 (1993)), a 63/55 Kdalton glycoprotein of the mouse milk fat globule (Stubbs et al, PNAS (USA) 87:8417 (1990)), and components 15/16 and GP55 of bovine and guinea-pig milk fat globule (Mather et al, Biochem. Mol. Biol. Int. 29:545 (1993)), respectively. Homologous portion of their sequences are shown in Table 6 below. When the complete gene was sequenced, it was found that the largest open reading frame of the BA46 cDNA clone encodes a protein of about 387 amino acids with an estimated molecular weight of about 43,123 Kdaltons. The actual correspondence of the cDNA cloned to the 46 Kdalton HMFG glycoprotein antigen isolated from the HMFG is shown by correlating the levels of mRNA with that of the expressed the 46 Kdalton HMFG antigen in different breast cell lines, and the binding of the monoclonal antibodies used in the cDNA screening to the pEX/LB21 fusion protein expressed in E. coli. In addition, five defined and distinct epitopes in the C-terminal end of the protein were determined by epitope mapping for two monoclonal antibodies of the cocktail used in the original screening of the cDNA library (Mc8 = DPRTG, and Mc16 = SSKIF) (See, Table 4 below). The two other monoclonal antibodies (Mc3, Mc15) neither bound to the fusion protein nor to any of the peptide hexamers used in the epitope mapping of the C-terminal region (amino acids 330 - 382) of the 46 Kdalton polypeptide. However, the two monoclonal antibodies, Mc3 and Mc15, bound to the full length recombinant polypeptide produced by expression in bacteria of the complete cloned cDNA sequence encompassing the entire ORF but not the signal peptide.

The amino acid sequence of the polypeptide deduced with the help of the PC/GENE DNA and the protein analysis programs (IntelliGenetics, Inc.) revealed the existence of homologies or sequence similarities with several functional domains. At the N-terminal end of the polypeptide, there is a hydrophobic region positioned after the Met start codon which most likely corresponds to a signal peptide. Cleavage most likely occurs between Val₂₁ and Ala₂₂, leaving a cleaved peptide of 21 amino acids plus the methionine. This cleavage results in a processed polypeptide of about 40,862 Kdaltons. Amino acids 46 to 48, RGD, represent a known cell adhesion sequence, and following this is an EGF-like domain of approximately 12 amino acids encompassing amino acids 55 to 66. The C-terminal end of the polypeptide starting at amino acid 69, comprises a domain with homology to the C1C2 region of human coagulation factors V and VIII, a portion of which is shown in Table 1 below. This sequence contains four potential N-linked glycosylation sites, all present in the C1C2-like domain, numerous potential O-linked glycosylation sites, disulfide linkages, and phosphorylation sites (e.g.

protein kinase C and casein kinase II sites). The greatest homology, however, is seen with the 66/55 Kdalton antigen MFGE8 isolated from the mouse milk fat globule (Stubbs et al., supra). These results permit the grouping of the 46 Kdalton HMFG polypeptide with growth factors and other molecules associated with cell adhesion interactions, e.g. associated with breast epithelial cells, that provide a possible autocrine/paracrine function. The 46 Kdalton HMFG antigen thus is likely a selectin-like molecule, which has the general structure of an N-terminal adhesion domain (lectin domain) followed by an EGF-like domain, a variable number of complement regulatory elements, a membrane-association domain (a single transmembrane sequence), and a short cytoplasmic tail. Although the 46-Kdalton antigen appears to lack a transmembrane domain, the C-type domain is very likely the means by which the 46 Kdalton HMFG antigen associates with the cell membrane by interaction with phospholipids. The possible cell interaction properties may be mediated via the cell adhesion sequence RGD since breast cells are known to possess integrins that have receptors for this sequence. The autocrine/paracrine properties may be mediated by the EGF-like sequence. The 46 Kdalton HMFG polypeptide is abundantly present in the HMFG and the expression of its mouse homologue is increased during lactation. Thus, the expression of the human 46 Kdalton HMFG and its mouse homologue are associated with differentiation in the breast. The production of the molecules is highly increased during lactation. Thus, except for periods of lactation, only cancer cells will express high amount of the 46 Kdalton HMFG antigen. Normal resting breast cells do not stain with anti-46 Kdalton HMFG antigen antibodies, showing the antigen to be substantially absent under these conditions.

Although the antibodies used to select the cDNA were specific to the Kdalton HMFG antigen, and happened to bind to breast carcinomas, the expression of the 2.2 kb mRNA that encodes the 46 Kdalton protein occurs in other cancer cell lines. The broad specificity found for cancers from tissues of different origins is attributable to a deregulation of this gene in neoplastic tumors such as carcinomas but not in normal tissue. Although the 46 Kdalton app. MW HMFG antigen may also be expressed by normal epithelial tissue cells, although at a lower level, it is processed in a way that blocks the epitopes that are exposed in the breast cell version of the polypeptide by, for example, producing alterations in its glycosylation. The HMFG mucin is also expressed in non-breast cancer cells such as non-breast carcinoma cells, but its altered processing in the pancreas, for example, leads to the exposure of different antigenic sites than in the breast.

The fusion protein is useful for assaying the presence of the 46 Kdalton HMFG

antigen or fragments thereof in sera obtained from cancer patients, such as patients suffering from breast carcinomas and also in milk of nursing mothers, among others. This fusion protein is also useful as an immunogen for generating second generation monoclonal and polyclonal antibodies of increased affinity for the antigen. These
5 antibodies may be used, among other applications, to further study the tissue distribution of this antigen and its involvement in the synthesis of its messenger RNA in improved immunoassays, and in the therapy of cancers of epithelial origin, both in vivo and ex vivo.

Many monoclonal antibodies raised against the C-terminus or the complete 46
10 Kdalton HMFG antigen serve to detect the respective epitopes present on this molecule by radioimmunobinding on HMFG membranes, whole milk, milk fractions, and on cancerous membrane material, such as those obtained from breast cancer patients. These monoclonal antibodies do not stain either normal breast tissue nor any other normal tissue when tested by immunohistology. Since some breast carcinomas have
15 very high levels of mRNA encoding the 46 Kdalton HMFG antigenic component, it is possible that second generation antibodies, both monoclonal and polyclonal made against the fusion protein have different, and possibly improved, specificity for detecting the 46 Kdalton HMFG antigenic component by immunohistopathology.

Northern blots using the cDNA clone in the present work showed that the
20 HMFG 46 Kdalton mRNA is present in most breast carcinoma cell lines tested, and in several non-breast carcinoma cell lines, and was still present but at lower levels in one lymphoid cell line (Raji). However, the expression levels of the 2.2 Kilobase RNA encoding the 46 Kdalton HMFG antigen detected vary considerably even amongst carcinoma cell lines. Carcinoma cell lines such as those from lung cells (A549), ovary
25 cells (SKOV3) and two breast cell lines (EII-G and HS578T) accumulated much more of the RNA transcript than other carcinoma cell lines. In other cases, such as in that of Her 2/neu, and the EGF-like receptor in breast and other carcinomas, the overexpression of certain genes has been correlated with prognosis of the disease. The overexpression of the 46 Kdalton HMFG antigen in neoplastic cells such as
30 carcinoma cells is thus correlatable with the development of cancer disease. Clearly, the 46 Kdalton HMFG antigen was shown herein to evidence epithelial specificity. However, certain epitopes of the 46 Kdalton HMFG antigen may have broader specificity for types of breast cells other than epithelial cells. The 46 Kdalton HMFG polypeptide is expressed significantly in malignant cells such as carcinoma cells due to
35 the deregulation of expression associated with malignancy. The 46 Kdalton HMFG antigen mRNA is highly expressed in cancer cells such as carcinoma cells of breast and

other origins. This is in contrast to its absence, in a form that is immunologically recognizable, from the corresponding normal cells.

Having cloned a portion of the cDNA of this molecule permitted the further deduction of the sequence of the encoded polypeptide C-terminus. It also permitted
5 the pursuit of further clones leading to the synthesis of recombinant DNA segments, polypeptides and fusion proteins containing the partial, and ultimately the complete 46 Kdalton amino acid sequence and fragments thereof as well as the preparation of a new generation of monoclonal antibodies against specific epitopes of this polypeptide. The hybrid DNA and fusion protein of the invention permitted the preparation of
10 polyclonal and monoclonal antibodies against the fusion protein of even greater specificity and/or affinity for any particular type of tissue, such as neoplastic cells of a specific organ or cancer type origin. The various cDNA clones obtained after the sequencing of the C-terminus allowed the deduction of the amino acid sequence of the 46 Kdalton app. MW HMFG antigen component of the HMFG system but the original
15 work led solely to a segment of slightly over 800 bases (217 amino acids) long before the appearance of an EcoR1 restriction enzyme site sequence, unbeknownst to the inventors, precluded its extension. The remaining portion, representing its N-terminus, would only be arrived at after a lengthy procedural path and trying numerous different methods.

20 The cDNA clones encoding the C-terminal 46 Kdalton HMFG antigen fragment were isolated by screening breast cell λ gt11 cDNA libraries using antibodies against the 46 Kdalton MW HMFG antigen. These libraries were made, as are most other cDNA libraries, by isolating mRNA from the breast cells, preparing cDNA using poly-dT primers or random primers and a reverse transcriptase enzyme, cutting with the
25 restriction enzyme EcoRI, and cloning into the λ gt11 expression vector at the EcoRI restriction site. The hybrid λ gt11 phages were then used to infect a susceptible bacterial strain, and when plaques developed on the bacterial lawn spread on petri dishes, the plaques were blotted onto a nitrocellulose membrane, the membranes incubated with anti-46 Kdalton MW HMFG antigen antibodies and the plaques that
30 bound the antibody were visualized by exposure to a photographic plate using a radioactively labeled second antibody against the first antibody. Positive plaques were then picked and their cDNA inserts isolated and sequenced. Although proven successful in obtaining cDNA fragments encoding the C-terminus of the 46 Kdalton MW HMFG antigen, even after many attempts this method did not facilitate the
35 extension of the DNA sequence in the 5' direction beyond the specific point shown in Table 1 below (the EcoR1 site). As it was learned much later, after a long road

plagued by unsuccessful cul-de-sacs, the major reason for the difficulties encountered in obtaining a full length DNA piece was the presence of an EcoRI restriction site at the specific site of the cDNA encoding the 46 Kdalton MW HMFG antigen represented by the 5' end of the C-terminal fragment isolated initially. The difficulties encountered

5 which precluded extending the DNA synthesis beyond this EcoRI site are inherent to the manner in which such cDNA libraries are made, and where the DNA fragments are cut and inserted into the λ gt11 vector: at an EcoRI site. Thus, the 46 Kdalton MW HMFG antigen cDNA fragments in this library encompassed sequences towards the 5' direction to this EcoRI site that were not obtainable with available antibodies

10 recognizing mostly protein epitopes encoded by regions located 3' to this EcoRI site. The antibodies utilized herein are the sole antibodies ever made by anyone against the 46 Kdalton HMFG antigen. Therefore, very few, if any, of the 46 Kdalton MW HMFG antigen cDNA clones could be extended beyond this EcoRI site. In addition, another consequence of the manner in which cDNA fragments are cloned into a phage is a low

15 probability (1 in 6) or a 1:6 proportion of cDNAs cloned in the right direction. When antibodies are used for screening a cDNA library, their effectiveness is reduced because only 1 out of 6 cDNA inserts in the library will be found to be in the right orientation and proper reading frame to code for the correct protein sequence. Therefore, the abundance of inserts containing sequences 5' to the EcoRI site in the 46 Kdalton MW

20 HMFG antigen cDNA in these cDNA libraries was much too low to allow their detection and/or isolation.

In addition to the above, another method of screening the hybrid phage library was also tried. In this method, the libraries were screened with radiolabeled 46 Kdalton MW HMFG antigen cDNAs which, regardless of their orientation or reading

25 frame, would bind to all inserts, but even here the desired sequences were present in amounts too low to be detected and consequently did not lead to obtaining DNA segments extending beyond this site. Still another method was utilized, the rapid amplification of cDNA ends (RACE) method to attempt to overcome the stumbling block encountered (Frohman, M.A. et al., PNAS (USA) 85:8998-9002, (1988)). The

30 RACE protocol generates cDNA fragments by PCR amplification of regions located between a single point in the transcript and either the 3' or the 5' end of the molecule. This is attained with the use of primers specially tailored to these two end regions. As the RACE method was applied herein, a short stretch of the target cDNA segment had to be known. Primers oriented in the 3' and 5' directions were designed, which

35 provided specificity to the amplification step starting from this region. The extension of the transcribed cDNA fragment starting from the ends of the mRNA was

accomplished with primers that annealed to the natural 3' end or to an added synthetic 5' end polyA tail. The isolation of the 5' end was attained by means of reverse transcription with a gene-specific primer. The polyA homopolymer was then appended to the 5' end of the fragment with the help of terminal transferases. This added a
5 polyA tail to the single stranded cDNA reaction product. The final amplification was accomplished using a hybrid primer, [oligo-dT of 17 residues linked to a unique 17 base oligonucleotide ("adaptor") primer], and a second gene-specific primer upstream of the first one. The amplified sequence was then cloned and sequenced. Although successful for obtaining some clones of the 3' end, the RACE protocol, even though
10 repeated numerous times, proved unsuccessful to complete the sequence of the cDNA encoding the 5' end of the 46 Kdalton MW HMFG antigen. In this case, the lack of success stemmed from the unexpected occurrence of a secondary structure in the 5' end of the 46 Kdalton MW HMFG antigen mRNA and an inadequate polyA tailing.

Another method involving the use of PCR technology utilized the direct
15 amplification of cloned cDNAs encoding the 5' end of the 46 Kdalton MW HMFG antigen from a breast cell λ gt11 cDNA library. Utilized as primers in this case were a downstream primer close to the 5' end of the cDNA encoding the known partial 46 Kdalton MW HMFG antigen and an upstream primer in the λ gt11 phage sequence. These two primers did help amplify inserts containing stretches of the unknown 5'
20 sequences. In this manner, ten amplified cDNAs were isolated, cloned and sequenced. Disappointingly, however, this proved to be another blind alley since all these clones had significantly different sequences. Some of these cDNAs appeared to extend the DNA fragment encoding the 46 Kdalton MW HMFG antigen beyond the impervious EcoRI restriction site, thus confirming its existence which had only been presumed up
25 to this point from the earlier attempts with antibody screening of the λ gt11 cDNA library, but then all the DNA sequences thus obtained diverged. These spurious results were probably due to mispriming and amplification of other DNA sequences in the process.

An improvement on the RACE method was then implemented that, instead of
30 using polyA tailing, used an AmpliFINDER anchor attached by ligation to the 5' end of a single stranded cDNA synthesized by reverse transcription of breast cell mRNA. Another improvement added to the protocol was the use of a heat-stable reverse transcriptase that is active at 52°C (conventional reverse transcriptases require 42°C). The higher temperature was used to overcome a previous problem by reducing any
35 secondary structure that might prevent the transcription of the mRNA by the reverse transcriptase enzyme. The AmpliFINDER anchor was attached to the 5' end and used

as a site for priming the PCR amplification of sequences between the 5' end and the site of the second primer in the known sequence of the cDNA encoding the 46 Kdalton MW HMFG antigen. The complete DNA sequence of the 46 Kdalton HMFG MW antigen was obtained with this AmpliFINDER RACE protocol and matched with the correct
5 sequence out of the ten sequences obtained from the cDNA library by the PCR amplification method utilized earlier. Thus, the authentic DNA sequence of the unknown portion of the ORF encoding the 46 Kdalton HMFG antigen without the 5' non-coding region was finally obtained.

This clearly illustrates the difficulties encountered and the unexpected and
10 unobvious path travelled to obtain the complete sequence of the cDNA encoding the 46 Kdalton MW HMFG antigen, and the deduced amino acid sequence of the product.

The cDNA clones obtained also allowed the preparation of a new generation of monoclonal antibodies that have sufficient specificity for application to cancer immunotherapy, sufficient staining ability for doing immunohistopathology, greater
15 ability for prognosis, diagnosis, imaging and therapy, and that can better identify the 46 Kdalton HMFG peptide and fragments thereof in the sera of cancer patients and milk of pregnant females and viral-infected patients, among others. The latter property makes these antibodies useful in the diagnosis of cancer and viral infection, and for the screening and early detection of the disease in humans.

20 This invention thus provides a polypeptide having the antibody binding selectivity and specificity of the 46 Kdalton MW HMFG antigen and/or homology to at least one of the light chains of clotting factors V and VIII and/or comprising a RGD and/or EGF-like segment. In one preferred embodiment, the polypeptide has the biological activity of the 46 Kdalton MW HMFG antigen, and more preferably the
25 polypeptide comprises the 46 Kdalton MW HMFG antigen itself or an antibody binding fragment thereof. The polypeptide or fragments thereof may be prepared by recombinant methods, which permit the arbitrary determination of its length and modification to be introduced at the DNA level. The polypeptide of the invention may be about 5 to 1,500 amino acids long, 90 to 500 amino acids long, more preferably
30 about 110 to 280 amino acids long, and still more preferably about 200 to 250 amino acids long. In another preferred embodiment, the polypeptide has the amino acid sequence shown in Table 4 (SEQ. ID No: 6) or that shown in Table 2 (SEQ. ID No: 3) or antibody binding fragments thereof, preferably about 5 to 100 amino acids long, and more preferably about 15 to 50 amino acids long. Particularly preferred are polypeptide
35 fragments which correspond to the specific epitopes which are recognized by the anti-46 Kdalton MW HMFG antigen antibodies prepared in accordance with this invention

and those containing the RGD and EGF-like segments. The non-glycosylated and glycosylated polypeptide of the invention may be synthetically prepared by methods known in the art such as chemical synthesis and the like. In addition, it may be produced as a non-glycosylated product in bacteria or in glycosylated form in plants or eukaryotic cells or hosts by recloning in appropriate expression vectors and transfection of receptive hosts.

The polypeptide of the invention also has anti-viral properties. Upon fractionation of the human milk fat globules, human milk globule membrane which is the globule's macromolecular component, and its acidic protein fraction retain the anti-viral activity. When the defatted milk fat globule fraction is separated into different fractions, the anti-viral activity of human milk remains mostly with the mucin complex. However, when the mucin complex is separated into its components the highest anti-viral activity is found with 46 Kdalton app. MW HMFG antigen. The 46 Kdalton app. MW HMFG antigen preferentially binds, e.g. simian and human rotaviruses when compared to the 70 Kdalton app. MW HMFG antigen and the 46 Kdalton MW HMFG antigen depleted milk mucin. The human milk fat globules, the macromolecular fraction and the milk mucin complex, which among other fractions contains the 46 Kdalton app. MW HMFG antigen, and the 46 Kdalton app. MW HMFG antigen were all found to inhibit viral infection, e.g., by rotavirus of human and simian origin, of cultured mammalian cells. The mucin complex was shown to inhibit viral infection with a 3000 fold greater specific activity than whole milk. These results are unexpected based on previous ambiguous reports relating to the effect of human milk on rotavirus, and the reported inhibitory effects of other milk components on this virus. The human 46 Kdalton app. MW HMFG antigen was also shown to bind to cells and cell extracts that are infected with human viruses such as rotavirus. Human strains of the virus, such as RRV, Wa, DS-1, P and ST-3, bind to the 46 Kdalton app. MW HMFG antigen in essentially equivalent amounts. Moreover, when sialic acid was removed from the 46 Kdalton app. MW HMFG antigen, its binding to virally infected cells was substantially reduced. This reduction in binding of the 46 Kdalton app. MW HMFG antigen to virus infected cells was found to be in the range of 30 to 60%. Thus, sialic acid may be required for the 46 Kdalton app. MW HMFG antigen to retain its binding activity as well as its anti-viral activity. Moreover, it is also possible that the anti-viral activity of milk mucins from other sources lacking sialic acid may be enhanced by sialylation. The polypeptide of this invention was also shown to inhibit in vitro viral infection of cells as well as viral gastroenteritis induced by viruses, e.g., rotaviruses, in an animal model. For instance, the administration of a murine rotavirus (EDIM) to suckling mice, caused

a 100% incidence of diarrhea in the mice. However, the simultaneous administration of the virus and the human milk macromolecular or acidic glycoprotein fraction (containing the 46 Kdalton HMFG antigen) to the suckling mice, reduced the diarrhea symptoms by 90%. In contradistinction, when a bovine milk-based formula or a control medium were administered, the rotavirus activity and the diarrheal symptoms remained undiminished. The various components of the human milk fat globule may be purified as described in the art. The polypeptide of this invention may be easily prepared for clinical use either by purification, by recombinant technology or peptide synthesis. The polypeptide may be purified from biological sources as follows. Human breast milk may be readily fractionated by published methods into a macromolecular component comprising the fat globule membrane. This component is distinct from oligosaccharides, lipids, immunoglobulins and other small proteins contained in milk. Likewise, whole human milk, the macromolecular fraction, and the fat globules may be defatted to produce fat globule membranes. The macromolecular fraction containing the milk mucin complex may be obtained by lipid extraction of fatty milk as described by Newburg, D.S., et al. (Newburg, D.S., et al, Pediatric Res. 31:22-28(1992)). The acidic glycoprotein fraction of milk may be obtained by isoelectric focusing as described by Yolken, R.M., et al. (Yolken, R.M., et al, J. Clin. Investigation 90: (1992)). Both these fractions have anti-viral activities that are, respectively, 3 and 38 times greater than whole milk. The milk mucin complex may be affinity-purified in accordance with published procedures (Ceriani et al., P.N.A.S.(USA) 74: 582-589 (1977)). Natural skim milk may be prepared by centrifuging unfrozen fresh milk, and removing the cream fraction that contains intact milk fat globules. When fresh milk is frozen and thawed, especially several times, sonicated, allowed to stand for a period of time, or exposed to temperature, the fat globules are generally disrupted. When the fat layer is then separated from the remainder or "processed skim milk", it contains mainly the lipid fraction of the cream (butter consisting of mainly triglycerides), while the milk fat globule membranes, the 70 Kdalton app. MW and the 46 Kdalton app. MW HMFG antigens are now mainly in the "processed skim milk". However, the amount is greatly increased in the "processed skim milk", the amount increasing with more vigorously freezing and thawing and/or sonication. Both the natural and the processed skim milk have anti-viral activity, with the latter evidencing higher activity. Curds and whey may be prepared as is known in the art, and will contain a certain proportion of the described components that have anti-viral activity. The milk mucin complex, in turn, may be further purified from the membranes using monoclonal antibodies as described herein, and the 46 Kdalton app. MW HMFG antigen may be separated from

the milk mucin complex or prepared by recombinant technology as described herein or simply by expression in a host, either eukaryotic or prokaryotic, transfected with a hybrid vector carrying the polynucleotide segment of this invention or a fragment thereof. The natural components are separable by traditional chromatographic and/or electrophoretic methods. The presence and identities of the components of the human milk mucin complex are readily determined using available, specific monoclonal antibodies. The gene encoding the 46 Kdalton app. MW HMFG antigen being provided herein, the gene product and variations thereof may be prepared by recombinant technology and expressed in recombinant microorganisms, plant and mammalian hosts as described by Larocca et al. (Larocca et al., Cancer Res. 51:4994 (1991); Larocca et al. Hybridoma 11:191 (1992); Larocca, et al., "Molecular Cloning and Expression of Breast Mucin Associated Antigens", in Breast Epithelial Antigens, p. 36, Plenum Press, Ceriani, R.L., ed, NY, NY (1991); and others). The amino acid sequence of the 46 Kdalton app. MW HMFG antigen is unrelated to any known immunoglobulin but was found to have significant homology to human epithelial cell proteins, the C1C2 domains of the human clotting factors V and VIII, the cell adhesion sequence RGD and an EGF-like sequence, a mouse milk fat globule 67 Kdalton app. MW protein MFG-E8, discoidin of amoebae, and the A5 antigen of xenopus brain, among others. Polypeptides having the viral binding characteristics of the 46 Kdalton app. MW HMFG antigen or fragments thereof may be prepared synthetically, by expression of genetically engineered vectors in transfected hosts and/or by adding a stop codon at a desired place in the DNA encoding the protein, by methods known in the art, or by purification from human milk of the 46 Kdalton app. MW HMFG antigen and subsequent partial hydrolysis. The synthetic polypeptide having the described characteristics may be prepared in different lengths by alteration of the DNA sequence encoding it and adding a stop codon where desired, as is known in the art, and expression of the thus altered gene or fragments thereof. The cDNA encoding the 46 Kdalton app. MW HMFG antigen has been cloned and fully sequenced as disclosed herein.

The novel anti-viral agent of this invention is suitable for use in most instances of viral infections, and particularly in cases where other therapies are either ineffective or clinically contraindicated. The agent of this invention exhibits additional advantages for the treatment of infants and children since, as already indicated, its components are normal constituents of human milk and the human diet. The present agent is thus unlikely to elicit toxic, immunological or allergic reactions in treated subjects. Because these agents are innocuous to the human body, the invention may be used without intervention of skilled medical personnel, for example, by adding it to foodstuffs, and

the like, that are normally sold over-the-counter in convenience stores or as food supplements available in grocery stores. This is a particular advantage for treating travellers or populations in underdeveloped countries where medical services are in short supply. The agent of this invention may be administered in combination with

5 other treatments, such as immune therapy, particularly treatments that act by independent mechanisms, to thereby provide a multi-pronged attack on the virus. Other anti-viral treatments may be combined with the present agent to provide a treatment compatible with other clinical needs of a patient, as well. For example, other milk components, such as oligosaccharides, α -interferon and trypsin inhibitors, known to

10 have anti-microbial and anti-viral activity, may be combined with the present agent. The inventors have found that components of human milk other than those encompassed by the invention failed to inhibit rotavirus infection in cell cultures. These agents, prepared by methods described in the art, include lipids, gangliosides, polar neutral glycolipids, non-polar glycolipids, triglycerides and fatty acids and neutral, acidic

15 and total oligosaccharides. The agent of the invention may be used alone, with a carrier or as an additive to a foodstuff, or in other compositions suitable for human consumption. Thus, an anti-diarrheic product may comprise a foodstuff, and an anti-viral effective amount of the polypeptide of the invention, either alone or in combination with other anti-viral agents and/or an agent selected from the group

20 consisting of defatted human milk fat globules, skim milk, the human milk macromolecular fraction, curd, whey, the human milk mucin-70 Kdalton app. MW glycoprotein-46 Kdalton app. MW HMFG antigen complex, and mixtures thereof. Each additional agent may be used alone or combined with one or more of the agents provided herein, or further combined with a foodstuff or food supplement for self-

25 administration. This composition may also be provided with other components including, but not restricted to, vitamin supplements, mineral additives, other nutritional additives, buffers, salts, flavoring compounds, diluents, thickeners, emulsifiers, preservatives, and anti-oxidants, such as would be familiar to a person skilled in the art, as would the amounts they are added in to the composition. The anti-diarrheic

30 composition or product may also comprise a binder such as gum tragacanth, acacia, corn starch or gelatin, excipients such as dicalcium phosphate, anti-clumping agents such as corn starch, potato starch, alginic acid and the like, lubricants such as magnesium stearate, sweetening agents such as sucrose, lactose or saccharin, flavoring agents such as peppermint, orange, wintergreen or cherry flavoring as well

35 as other known artificial and natural flavoring compounds. Sustained-release preparations and formulations are also within the confines of this invention, and may

contain further ingredients as is known in the art. A coated composition, or otherwise modified forms of the preparation are also contemplated herein such as coatings of shellac, gelatin, sugar and the like.

Any material added to this product should be pharmaceutically-acceptable and

5 substantially non-toxic in the amounts employed. Other excipients may be added to the formulation such as those utilized for the production of ingestible tablets, troches, capsules, elixirs, suspensions, syrups and wafers, among others and the product may then be provided in these forms. In one preferred embodiment, the polypeptide, whether glycosylated or non-glycosylated, may be compounded with other anti-viral

10 human milk components as well as other anti-viral and anti-microbial agents as indicated above. In another preferred embodiment, the product comprises the mucin complex or mixtures thereof. The polypeptide of this invention may be present in the anti-diarrheic product in an amount of about 0.01 to 99.9 wt% of the composition, and preferably about 0.1 to 20.0 wt%. However, other amounts of the agent may also be

15 present in the product. The amount of the agent in the anti-diarrheic product may be varied, and/or the frequency of administration increased, depending on the severity of the infection, the general health and nutritional status of the subject, and whether or not other anti-viral agents are being administered as well. Foodstuffs suitable for use in the anti-diarrheic product of the invention are milk, juices, cereals, chewing gum,

20 crackers, candies, meats, vegetables and fruits, blended or otherwise as baby food for example, and cookies, among others. In another embodiment, the foodstuff of the product provided herein may be infant formula, milk, milk substitutes, baby foods, rehydration formula, and vitamin supplements, among others. This product may be specifically formulated for the palate of youngsters, when applied to the treatment of

25 infants or small children. The polypeptide may be provided in an anti-diarrheic kit comprising an anti-diarrheic composition comprising the polypeptide itself or a fragment thereof having anti-viral properties, either alone or with an agent selected from the group consisting of defatted human milk fat globules, skim milk, the human milk macromolecular fraction, curd, whey, the human milk mucin-70 Kdalton app. MW

30 glycoprotein-46 Kdalton app. MW HMFG antigen complex, other anti-diarrheic agents and additives mentioned above, and mixtures thereof, and a pharmaceutically acceptable carrier; and instructions for its use. The anti-diarrheic composition of this kit may be administered in an amount of the anti-diarrheic product of about 0.1 to 1000 mg/kg body weight/day, and more preferably about 1 to 50 mg/kg body

35 weight/day. Other amounts, however, may also be administered. It is understood that the more active fractions, such as the 46 Kdalton app. MW HMFG antigen may be

administered at a lower dose, whereas the lesser active fractions such as the defatted milk fat globule may be administered at a higher dose. Other amounts may also be administered. This kit is formulated for the therapeutic treatment of subjects afflicted with or at risk of diarrheal conditions associated with viral infection. The additives for

5 the anti-diarrheic composition may be vitamin supplements, mineral additives, other nutritional additives, salts, buffers, flavoring compounds, diluents, thickeners, emulsifiers, preservatives, and anti-oxidants, among others, such as would be familiar to a person skilled in the art. Included within the invention, is an embodiment wherein the above anti-diarrheic compositions further comprise varying amounts of other

10 components such as foodstuffs. Suitable are all kinds of foods including milk and milk supplements. The anti-diarrheic composition or the product of the invention may also be modified to include varying amounts of water and ingredients suitable to the clinical needs of the subject. The anti-diarrheic composition may be mixed with a drink, soup, and the like (liquid) or a foodstuff (solid) for self-administration. The composition may

15 be added in an anti-viral amount, and may be provided in bulk or in unit form. An anti-diarrheic kit is also provided that comprises in separate containers, a foodstuff, and an anti-viral effective amount of the polypeptide of the invention, either alone or with an agent selected from the group consisting of defatted human milk fat globules, skim milk, the human milk macromolecular fraction, curd, whey, the human milk mucin-70

20 Kdalton app. MW glycoprotein-46 Kdalton app. MW HMFG antigen complex, and mixtures thereof, and optionally a pharmaceutically-acceptable carrier, and instructions for use of the kit. For purposes of identification of the components, the apparent molecular weight (app. MW) of the glycoproteins of the invention may be determined by SDS-polyacrylamide gel electrophoresis using standard techniques described in the

25 art. For example, defatted human milk fat globule membranes may be dissolved in a solution containing 1% sodium dodecyl chloride (SDC) and heated to dissolve the glycoproteins, applied to a 3-30% polyacrylamide gel and electrophoresed with appropriate molecular weight standards run in a parallel lane, the apparent molecular weight (app. MW) of the mucin complex obtained is approximately 400,000 Kdalton

30 app. MW or greater. The apparent molecular weights of other proteins may be determined in a similar manner. The 46 Kdalton and the 70 Kdalton app. MW glycoproteins associated with the milk mucin complex may also be identified by binding to the specific monoclonal antibodies Mc16 and Mc13, respectively (Larocca et al., Cancer Res. 51:4994 (1991); Peterson et al., Hybridoma 9:221-235 (1990), supra).

35 The milk mucin, also referred to as breast mucin, may be identified in the complex by binding to the monoclonal antibody Mc5 described by Peterson, J.A., et al. (Peterson,

J.A., et al., Hybridoma (1990), supra). If the defatted human milk fat globule is dissolved in SDS under reducing conditions such as in the presence of 0.5% beta-mercaptoethanol, the 70 Kdalton app. MW HMFG glycoprotein runs as a doublet with an apparent molecular weight of 70 Kd, that may be further identified by binding to the monoclonal antibodies Mc13 and McR2. The 46 Kdalton app. MW HMFG glycoprotein under the same conditions, appears as a doublet with an apparent molecular weight of 46 Kd, as identified by binding, among other antibodies evidencing specificity for different epitopes on the molecule, to the monoclonal antibodies Mc3 and Mc16 described by Larocca, et al. (Larocca et al., Cancer Res. 51:4994 (1991), supra). The milk mucin, under reducing conditions, is seen as a band of approximate 400,000 Kdalton apparent molecular weight and may be identified by binding to the monoclonal antibody Mc5 described by Peterson, J.A., et al. (Peterson, J., et al., Hybridoma (1990), supra). If the milk mucin, the 70 Kdalton app. MW HMFG glycoprotein, and the 46 Kdalton app. MW HMFG glycoprotein are treated to remove oligosaccharides, their apparent molecular weights, as determined by polyacrylamide gel electrophoresis, appear to decrease. This invention additionally provides a method for retarding the onset of, or countering, viral infection, such as that associated with rotaviruses, of a mammalian cell comprising contacting the cell in a nutrient medium with an anti-viral infection effective amount of the polypeptide of this invention or fragments thereof, either alone or with an agent selected from the group consisting of defatted human milk fat globules, skim milk, the human milk macromolecular fraction, curd, whey, the human milk mucin-70 Kdalton app. MW glycoprotein-46 Kdalton app. MW HMFG glycoprotein complex, and mixtures thereof. In one preferred embodiment of the invention, the anti-diarrheic composition comprises the 46 Kdalton app. MW HMFG glycoprotein. In another embodiment, the composition comprises the polypeptide of this invention and the mucin complex. Both of these agents may be administered alone and/or with defatted human milk fat globules, and/or whey, and/or curd, and/or skim milk, and/or the HMFG macromolecular component, and/or the 46 Kdalton app. MW HMFG glycoprotein, fragments thereof having anti-viral activity, and/or mixtures thereof. Although the complete removal of glycosides from the mucin complex was shown to reduce the anti-viral activity of the glycoprotein by at least 40-60%, agents having varying levels of glycosylation may be used, since they retain some activity. Also disclosed herein is a method of retarding the onset of, or countering, viral infection of a subject's cells comprising administering to a subject at risk for, or suffering from, a viral infection, such as a rotavirus infection an anti-viral effective amount of the composition of this invention or mixtures thereof, or a composition

comprising the polypeptide of the invention and a pharmaceutically-acceptable carrier and/or a foodstuff and/or other additives as described above. The composition may incorporate other anti-viral or anti-microbial agents, as suitable for effective treatment of a rotavirus infection taking into account the age, general health, and nutritional
5 status of the subject. Other compositions of the agent of the invention and further comprising, e.g., the macromolecular fraction of the defatted milk fat globule membrane and the acidic fraction, are also contemplated herein.

The onset of, or countering, infantile gastroenteritis associated with viral infection, such as rotaviral infection, may be retarded or completely prevented by
10 administration to an infant or child in need of the treatment an anti-viral infection effective amount of the polypeptide of the invention, either alone or with an agent selected from the group consisting of defatted human milk fat globules, skim milk, the human milk macromolecular fraction, curd, whey, the human milk mucin-70 Kdalton app. MW glycoprotein-46 Kdalton app. MW HMFG antigen complex, and mixtures
15 thereof, and optionally a pharmaceutically-acceptable carrier and/or other agents and infant foodstuffs such as formula, milk, juice, and the like, as described above. The above method may be used for the prophylaxis of the disease, particularly where demographic and public health information suggests significant risk of infection. When symptoms indicate the onset of infection, the method may also be applied
20 therapeutically. The agent of this invention may be present in the infant formula in an amount from 0.01 to 99.9 wt%, and more preferably about 0.1 to 2.0 wt% of the composition. Other amounts of the agent, however, may also be used. As this product is formulated for the prophylactic or therapeutic treatment of infants and children afflicted with or at risk of diarrheal conditions associated with viral infection,
25 the infant food product may include varying amounts of infant formula, juices, foods, milk or milk supplements, among others. This anti-diarrheic infant product may also include vitamin supplements, water, mineral and other nutritional additives, salts, buffers, flavoring compounds, diluents, thickeners, emulsifiers, preservatives, encapsulation agents, glycosidase inhibitors, protease inhibitors, and anti-oxidants,
30 such as would be familiar to a person skilled in the art. The infant formula may also be modified to include varying amounts of water and other solutes to meet other clinical needs of the infant or child. The human milk components of this invention being routinely consumed and consisting of biological molecules, their administration will neither require clinical precautions nor medically trained personnel. Accordingly,
35 the present products may be sold over the counter. Also provided herein is a method of retarding the onset of, or countering, diarrhea associated with viral infections, such

as rotavirus infection, in a subject's cells comprising administering to a subject in need of such treatment a composition comprising an anti-viral effective amount of the polypeptide of the invention, either alone or with an agent selected from the group consisting of defatted human milk fat globules, skim milk, the human milk macromolecular fraction, curd, whey, the human milk mucin-70 Kdalton app. MW antigen-46 Kdalton app. MW HMFG antigen complex, and mixtures thereof, and optionally a pharmaceutically-acceptable carrier and/or a foodstuff. Because of minimal side effects associated with the agent used in this method, the agent may also be administered for diarrheal symptoms regardless of etiology to prevent secondary outbreaks associated with rotavirus infection. The polypeptide of the invention is also suitably applied to retard the onset of, or counter, diarrhea associated with viral infection in an immunodeficient subject comprising administering to an immunodeficient subject an anti-viral effective amount of the polypeptide, either alone or with an agent selected from the group consisting of defatted human milk fat globules, the human milk macromolecular fraction, skim milk, curd, whey, the human milk mucin-70 Kdalton app. MW antigen-46 Kdalton app. MW HMFG antigen complex, and mixtures thereof, optionally comprising a pharmaceutically acceptable carrier and/or foodstuffs as described above. Such immunodeficiencies may result from genetic dysfunction, organ transplant, disease induced conditions or as a consequence of medical treatment with drugs, among others. Other agents that may be added to the composition for this particular application are bulking agents, carbon black, high fiber additives, encapsulation agents, protease inhibitors, glycosidase inhibitors, and carrier lipids, optionally micellar, among others. These may be present in amounts known in the art. Specific applications of the above method are in cases of, e.g., transplants such as bone marrow, kidney, heart and other organ transplants. Transplant patients receiving immunosuppressant drugs may also benefit from this anti-diarrheic treatment. The above preventative and therapeutic methods may be practiced by administering the agent provided herein as part of an anti-diarrheic composition also comprising a carrier or a product such as a foodstuff, as described above. Suitable foodstuffs are milk, juices, cereals, powdered grains, candies, confections, cookies, meats, vegetables and fruits, put through a blender or otherwise processed, and crackers, among others.

A pharmaceutical or foodstuff composition for preventative, therapeutic, and/or imaging purposes may comprise the polypeptide of the invention and a non-proteolytic carrier. The carrier may be a pharmaceutically-acceptable carrier or in some cases a foodstuff. This composition may be produced in bulk or in unit form. In the latter case, each unit may contain an antibody binding effective amount (in vitro and ex vivo

assays), an anti-viral effective amount (anti-viral therapy), or an anti-cancer therapeutic amount (cancer therapy) of the polypeptide. The pharmaceutical or foodstuff composition is intended for in vivo animal use, which includes human administration. Each dose preferably contains about 0.1 to 1000 mg of the polypeptide per kg body weight, and more preferably about 10 to 500 mg/kg. However, other amounts may also be administered as a practitioner would know. Any pharmaceutically-acceptable carrier may be utilized for the preparation of the composition intended for in vivo therapy or diagnostic use. Examples of suitable carriers and other additives are flavorings, preservatives, bulking materials, stabilizers, adjuvants, coatings, colorants, and salt solutions such as saline, oils or solids, among others as known in the art. However, any liquid or solid carrier which does not hydrolyze the polypeptide is suitable particularly for in vitro and ex vivo uses. The pharmaceutical or foodstuff composition as well as the polypeptide itself are best kept under refrigeration and/or frozen as is known in the art. The polypeptide and the pharmaceutical or foodstuff composition may be vacuum dried and packaged in a sterile container for transportation to their destination. The composition may comprise about 0.01-99.99 wt% of the polypeptide, and preferably about 0.1-10 wt%, the remainder being the carrier when the composition is intended for in vitro application only, in which case the carrier need only be non-proteolytic. Also provided herein is a fusion protein, which comprises the polypeptide described above, and a second antigenic polypeptide or an antibody binding fragment thereof which is operatively bound to the polypeptide. The polypeptide of the invention may be bound to a fragment of the second antigenic polypeptide as peptides about 10 to 1000 amino acids long and 10 to 1100 amino acids long, respectively, and preferably about 15 to 300 amino acids long and 200 to 400 amino acids long, respectively. However, other sizes of the polypeptides, and/or fragments thereof, either larger or smaller, may be utilized as long as their antibody binding capability is preserved. Any polypeptide is suitable as the second antigenic polypeptide as long as it acts as an antigen to elicit the formation of antibodies by a mammal when intended for use in a multiple antibody assay. The second antigenic polypeptide may also be chosen by some other property suitable for the identification and/or use of the fusion protein, such as a function other than antigenicity. By means of example, the second antigenic polypeptide may be a protein such as β -galactosidase or a fragment thereof. Both, the polypeptide of the invention and the fusion protein may be prepared by methods known in the art, either synthetically or by expression of a DNA fragment that encodes it as described herein or by cloning and expression utilizing other methods known in the art. The fusion protein may be prepared, for instance, by cloning a

recombinant DNA encoding, in reading frame, the gene's segment into a vector carrying the DNA encoding the second polypeptide, transfecting a suitable host, and expressing it in a host.

Also part of this invention is an antibody having high affinity, selectivity and
5 specificity for the 46 Kdalton HMFG antigen of the invention or fragments thereof containing one or more of its epitopes. These antibodies are of greater specificity for cancer cells than the original antibodies used to isolate the mRNA because they identified epitopes on the polypeptide that are probably more accessible to the antibody when the polypeptide is on the cell. Monoclonal antibodies Mc8 and Mc 16 bind to the
10 C1C2 domain of the 46 Kdalton HMFG antigen, that is considered to be the domain most likely buried in the cell membrane. Also antibodies against the cell adhesion sequence RGD and the EGF-like sequence are intended for modifying the function of the 46 Kdalton HMFG antigen in cancer cells and thus diminish the cancerous properties of these cells. Also, the antibodies that bind to more accessible epitopes
15 evidence greater applicability in immunohistochemistry. Methods for raising antibodies are known in the art and need not be described herein. For instance, the amino acid sequence corresponding to a desired epitope may be utilized as a hapten or antigen and with the aid of a carrier protein and adjuvants administered to an animal to raise epitope-specific antibodies. The B-cells producing these antibodies may then be utilized
20 to produce hybridomas by methods known in the art that express highly specific antibodies for selected epitope. Particularly preferred are monoclonal antibodies. The antibodies raised against the biologically pure polypeptide or epitopic fragments thereof have increased affinity and/or specificity for the polypeptide. Typically, the affinity constant may be about 10^8 to 10^5 M^{-1} , and in some cases greater than 10^8 M^{-1} .
25 Particularly preferred embodiments of the antibody also have affinity for the C and/or C2 regions of clotting factor VIII (light chain) and the RGD and/ or EGF-like segments thereof. Still another preferred antibody of the invention are binding active Fab, (Fab)₂, and Fab' fragments thereof. Also preferred are binding active single chains of the antibody or the fragments. A composition intended for in vitro use comprises an anti-
30 46 Kdalton HMFG antigen antibody having an affinity constant of about 10^{10} to 10^5 M^{-1} , or binding fragments thereof, and a non-proteolytic carrier. When intended for in vivo or ex vivo use, the carrier must be a pharmaceutically-acceptable carrier or a foodstuff. When in unit dose form, the antibody is typically provided in an amount of about 0.001 to 100,000 mg, and more preferably about 10 to 500 mg. However,
35 other amounts are suitable. Any pharmaceutically-acceptable carrier is suitable as indicated above. Other ingredients may also be contained in the composition such as

radionuclides, chemotherapeutic drugs, interferon, toxic agents such as ricin A-chain, abrin A-chain, saline salt solutions, preservatives, flavors, bulking agents, colorants and buffers, among others, as is known in the art. The preparation of all the compositions may be undertaken by admixing the polypeptide or the antibody with the
5 pharmaceutically-acceptable carrier under non-proteolytic conditions, then vacuum dried and packaged in sterile containers or provided as a sterile solution.

The present antibodies may be applied to detecting the presence in a biological sample of the 46 Kdalton HMFG antigen or fragments thereof, by addition to a biological sample suspected of containing the polypeptide, adding thereto an antibody
10 selectively binding the 46 Kdalton HMFG antigen under conditions effective to form an antibody-polypeptide complex, determining the amount of complex formed, and preparing the result with a control run without the sample. This method is suitable for detecting the presence of the polypeptide or fragments thereof in biological samples such as animal cells, cell extracts, body fluids such as milk, and aids in the
15 determination of whether epithelial cells or neoplastic tumor cells such as those from breast and other tissues which are of epithelial origin and express the 46 Kdalton HMFG antigen, are present in the sample. Typically, all body fluids are encompassed herein. Examples are serum, plasma, urine, breast fluid, human milk, tissue biopsies, and fine needle aspirates. The sample may be previously treated, e.g., to avoid
20 interference by metals, non-specific proteins, fats, nucleic acids, and the like as is known in the art. The biological sample may also be diluted in order that the protein content be in a range of about 0.0001 to 10 mg/ml, and more preferably about 0.001 to 0.1 mg/ml. The antibody may be added in an amount of about 0.0001 to 1.0 mg/ml of sample, and more preferably about 0.001 to 0.1 mg/ml of sample. Other conditions
25 for the assay utilized, including the following. The sample may be homogenized and centrifuged to remove particulate material and fatty material. Detergents may be added to dissolve membranes, solubilize fatty material and reduce background. Also added may be carrier proteins such as bovine serum albumin to reduce non-specific binding of the antibodies, and chelators to remove interfering divalent metal ions. The
30 antibody may be monoclonal or polyclonal, although preferred are monoclonal antibodies which provide high sensitivity. Even more preferred are antibodies of affinity constants of about 10^8 and up to about 10^{10} M^{-1} . The determination of the presence of any complex formed between the antibody and the polypeptide may be done by a variety of methods known in the art. By means of example will be cited
35 herein the further addition of a labeled anti-constant region immunoglobulin to form a labeled double antibody-polypeptide complex. The label may be a radiolabel, a

fluorescent label, an enzyme label or biotin to be later detected as a conjugate of avidin, streptavidin or magnetic bead, among others. After this step, the amount of label bound to the complex may be assessed by methods known in the art. This method may be applied to determining the presence in a biological sample of epithelial
5 cells or the 46 Kdalton HMFG antigen itself or a fragment thereof by adding to a biological sample suspected of containing cells of epithelial origin or the antigen or a fragment thereof such as cancer patient's serum samples an anti-46 Kdalton HMFG antigen antibody, and determining the amount of any complex formed therebetween. This method is particularly well suited for biological samples such as bone marrow, milk
10 and serum samples. However, it may be practiced with samples of other origins as well. The steps are in general conducted as described above and the determination of the presence of malignant tumor cells of epithelial origin or anti-viral factors in milk may be done by the identification, either qualitative or quantitative, of any complex formed with the antibody as already described. The detection may also be undertaken by
15 assaying for the presence of ribonucleic acid (RNA) encoding the 46 Kdalton HMFG antigen using nucleic acid probes based on sequences such as the ones shown in Table 1 and 4 or fragments thereof, and methods known in the art such as PCR (Erlich, H.A., in PCR Technology: Principles and Applications for DNA Amplification, Stockton Press (1989)).

20 The antibody may also be applied to the in vivo imaging or therapy of malignant tumors of epithelial origin by administering to a subject suspected of being afflicted by a cancer of epithelial origin, or undergoing cancer therapy, a polypeptide binding effective amount of an anti-46 Kdalton HMFG antigen antibody of this invention effective to deliver it to an area of the subject's body suspected of having the
25 neoplastic tumor to form an antibody-cell polypeptide complex. The antibody may carry a radiolabel or other anti-cancer therapeutic agent or a detectable label capable of binding to the antibody at a site other than polypeptide binding site may be administered, and then non-invasively detecting the presence of the label associated with any complex formed in the subject's body. The antibody may be administered at
30 a concentration of about 0.5 to 50 mg/ml, and more preferably about 5 to 20 mg/ml. A total of about 1 to 50 ml of the antibody composition may be given at any one particular time. The regimen of administration may be by single or repeated dosage, or the antibody may be administered in a continuous manner in order to image or to continuously suppress the presence of tumor cells. The antibody may be administered
35 in a pharmaceutical composition as described above, or in any other suitable form. The administration of the antibody may be conducted by intravenous, intraperitoneal,

intracavitary, lymphatic, intratumor or intramuscular routes, among others. Other routes are also suitable if they do not hydrolyze the peptide links of the antibody. The administration of a detectable label may be conducted by utilizing a labeled anti-constant region immunoglobulin, protein G or A or a binding fragment thereof, and then
5 detecting the amount of label bound to the complex. These technologies are known in the art and need not be further described herein.

The polypeptide and fusion protein of the invention may be applied to detecting the presence in a biological sample of anti-46 Kdalton HMFG antigen antibodies, indicative of a growing neoplastic tumor of epithelial origin such as a carcinoma, by
10 adding to a sample obtained from a patient suspected to be afflicted with this type of cancer an antibody binding effective amount of the polypeptide of the invention and determining the presence of any complex formed. The sample may be treated as indicated above to eliminate interference by other proteins and/or components present in the sample. In the case of blood, serum may be obtained first, and then the serum
15 may be treated by adding normal human or bovine serum, and/or bovine serum albumin (BSA) is used as a blocking agent to reduce non-specific reactivity. The polypeptide may be recombinantly produced and is typically added to the sample in an amount of about 0.00001 to 1.0 mg/ml sample, and more preferably about 0.0001 to 0.1 mg/ml sample. However, other amounts may also be utilized as seen for different assay
20 procedures, and the amount of antibody in the sample may be controlled by dilution. Optimal ranges of antibody in the sample are about 0.00001 to 0.1 mg/ml, and more preferably about 0.0001 to 0.01 mg/ml, but, other amounts may also be utilized. The steps of this method are practiced as described above, including the determination of the presence of antibody-polypeptide complex. The conditions for the assay are in
25 general those known in the art for not denaturing proteins and the overall variables, such as pH, temperature and the like may be adjusted without undue experimentation. The presence of an anti-46 Kdalton HMFG antigen antibody in a sample may also be detected by adding to a sample suspected of comprising the antibody a binding effective amount of the fusion protein of this invention under conditions effective to
30 form an antibody-fusion protein complex, adding thereto an anti-second polypeptide antibody under conditions effective to form a double antibody complex, and determining the presence of any double antibody complex formed. This method is preferably practiced with an anti-second polypeptide monoclonal antibody. The amount of anti-second polypeptide antibody added to the sample is preferably about 0.00001
35 to 0.1 mg/ml sample, and more preferably about 0.0001 to 0.01 mg/ml of sample. However, other amounts may also be utilized, and the sample may be pretreated prior

to the addition of the fusion protein in various manners, such as by dilution and/or elimination of interfering components. These steps are undertaken as is known in the art and need not be further described herein. Solid-phase type of assays are preferred, and among these, more preferred is the Ceriani et al. method (Ceriani, R.L. et al., Anal. Biochem. 201:78 (1992)). However, other assays are also suitable and therefor, contemplated herein.

The polypeptide of the invention is also useful for vaccinating against neoplastic tumors and cancer by its administration or that of antigenic fragments thereof in amounts effective to elicit an endogenous immunological response. This in vivo method may also be utilized in cancer patients to induce an immune response against their exposed neoplastic epithelial cells carrying the corresponding epitopes. The vaccinating polypeptide may be administered to a subject including a human in an amount of about 0.1 to 100 mg/ml, and more preferably about 2 to 50 mg/ml. Typically, any dose may be delivered in about 0.1 to 50 ml, and more preferably in about 1 to 10 ml of the carrier. The vaccinating composition may be administered in a single dose or it may be administered repeatedly and/or on a continuous basis for periods of up to about 6 months, and sometimes in excess of one year, alone with a carrier or in conjunction with one or more adjuvants, and the like, as is known in the art. More prolonged periods of time are also encompassed for vaccination according to this invention.

A therapeutic agent may be delivered in vivo to target epithelial cells, such as neoplastic cells by binding it to the anti-46 Kdalton HMFG antigen monoclonal antibody provided herein at a site other than the antigen binding site, administering to a subject afflicted with a neoplastic growth of epithelial origin a therapeutically effective amount of the antibody-bound therapeutic agent under conditions effective to deliver the agent to the target cells environment, and allowing the antibody carrying the therapeutic agent to bind to the target cells to permit the therapeutic agent to exert its effect on the cells. This in vivo method may be utilized for treating cancer patients that are afflicted with cancers of epithelial origin, e.g. breast cancer. The therapeutic agent may be any anti-cancer agent known in the art, such as radionuclides, chemotherapy drugs, toxic agents such as ricin A-chain, abrin A-chain, and others. The therapeutic agent is typically bound to the antibody by means known in the art. More specifically, a radionuclide such as ¹³¹I may be bound to the antibody by oxidation of amino acids such as tyrosine, or ⁹⁰Y may be attached via a chelator, and the conjugate injected intravenously or intraperitoneally into humans afflicted with neoplastic tumors such as breast carcinomas among others to inhibit the growth of the

tumor. (e.g., for mice, Ceriani, et al, Cancer Res. 48:4664-4672(1988)). The antibody-bound therapeutic agent may be administered to the subject in an amount of about 1 to 100 mg/ml, and more preferably about 2 to 20 mg/ml. Typically, any dose will consist of about 1 to 50 ml of carrier and more preferably about 2 to 10 ml carrier.

- 5 The antibody-bound therapeutic agent may be administered as a single dose, in multiple doses, or on a continuous basis for periods of up to about 6 months, and sometimes in excess of one year. More prolonged periods of time are also encompassed for treatment herein.

The therapeutic agent may also be delivered ex vivo to target cells such as
10 neoplastic tumor cells by adding the antibody-bound therapeutic agent to a sample obtained from a patient afflicted with cancer under conditions effective to promote the formation of an antibody-cell polypeptide complex, allowing the agent to exert its effect on the cells, and returning the sample to the subject. Non-conjugated antibody may also be added to the sample in the presence of complement, which causes lysis
15 of the cells, prior to returning the sample to the subject. In general, the steps of this method may be practiced as described above for other applications, particularly in terms of the preparation of the biological sample, and binding of the therapeutic agent to the antibody as well as the addition of the antibody-bound therapeutic agent to the sample. The sample may be returned to the subject by means known in the art. For
20 example, the already treated sample may be returned to a subject's body in sterile form by the intravenously, intracavitary, intraperitoneal, and intratumor routes, among others. However, other routes known in the art may also be utilized.

Also provided herein is a polynucleotide encoding the polypeptide of this invention including all redundant DNA and RNA sequences. The polynucleotide is
25 provided either as a double stranded or single stranded DNA containing the coding or the non-coding strand of the polynucleotide. The fragments of the polynucleotide may be of about 15 to 3000 bases, and more preferably about 30 to 300 bases. Both the double stranded and the single stranded DNAs discussed above may be in labeled form. The labeling may be conducted as is known in the art with radioactive atoms such as
30 ^{32}P , ^{14}C , ^3H , ^{33}P , and the like. However, other radionuclides may also be utilized. Particularly preferred is a polynucleotide encompassing the DNA sequence shown in Tables 1 and 4 of this patent and redundant sequences thereof encoding the polypeptide of the invention or fragments thereof comprising about 9 to 3000 bases, and more preferably about 18 to 300 bases. However, fragments of other sizes may
35 also be utilized and are encompassed herein. Also part of this invention is a polyribonucleotide encoding the polypeptide of the invention or fragments thereof. The

polyribonucleotide segments may be about 9 to 3000 bases long, and more preferably about 18 to 300 bases long. However, other fragment sizes are also encompassed herein. Still part of this invention is a non-coding strand of a polyribonucleotide having a sequence complementary to that of the polyribonucleotide described above. This
5 polyribonucleotide sequence is capable of hybridization to the coding RNA strand or to the non-coding strand of the corresponding DNA. In a particularly preferred embodiment the polyribonucleotide is provided in labeled form.

A hybrid polynucleotide, encoding a fusion protein comprising the above polypeptide and a second antigenic polypeptide or antibody binding functional fragment
10 thereof bound thereto. The hybrid polynucleotide may be about 15 to 4000 bases long, and sometimes longer, and more preferably about 50 to 1,800 bases long. However, other size polynucleotides are also encompassed herein. Also provided herein is a hybrid polyribonucleotide encoding a fusion protein comprising the polypeptide of the invention and a second antigenic polypeptide, or antibody binding
15 fragment thereof bound thereto and all redundant fragments thereof and complementary sequences thereof. The hybrid polyribonucleotide encoding the fusion protein may be about 15 to 4000 bases long, and more preferably about 50 to 1,800 bases long. Fragments thereof may be about 9 to 100 long, and more preferably about 15 to 70 bases long. The hybrid polynucleotide encoding the fusion protein is provided
20 as a double stranded DNA which encompasses the coding or non-coding strand encoding the fusion protein or fragments thereof. The latter polynucleotide provided herein is a polynucleotide comprising DNA sequences complementary to the polynucleotide encoding the fusion protein. Both the DNA and RNA sequences encoding the fusion protein may be provided in labeled form. Particularly useful labels
25 are ^{32}P and others known in the art. The DNAs and RNAs are labeled by methods known in the art.

The presence of a polynucleotide encoding the 46 Kdalton HMFG antigen or a fragment thereof in a sample may be detected by adding to the sample a hybridization effective amount of a labeled DNA comprising the non-coding strand of a
30 polynucleotide encoding the polypeptide or hybrid polypeptide of the invention under stringent conditions effective to hybridize any polynucleotide having a complementary sequence of at least 15 bases thereto, and detecting the presence of the DNA-complementary polynucleotide hybrid. The sample may be a biological sample or it may be a laboratory sample. If the sample contains cells where the polynucleotide is
35 located, the cells may need to be lysed, and optionally the DNA isolated from the remainder materials. This may be done by methods known in the art. The sample may

be diluted and/or otherwise prepared for the melting of double stranded polynucleotide sequences present therein. The melting step is conducted as is known in the art. In general, the sample is prepared by lysing the cells in 4 M guanidinium isothiocyanate to denature protein and prevent RNase activity. Extracts are run on a cesium chloride
5 density step gradient ultracentrifugation where RNA, DNA and protein are separated according to their relative densities. DNA and RNA may be further purified by extraction with organic solvents, and concentrated by precipitation in 70% ethanol. (Sambrook et al, in *Molecular Cloning: A Laboratory Manual*, Second edition, Cold Spring Harbor Press, N.Y., (1989)). Melting may be accomplished by raising the
10 temperature of the sample about 20°C over the T_m of the DNA, or by raising the pH to above 12. To the melted DNA may be added a hybridization effective amount of the labeled non-coding DNA strand. Suitable conditions for the hybridization of DNA-DNA segments are known in the art. The degree of stringency is determined by the degree of complementarity of the sequences desired to be hybridized. In general, when more
15 stringent conditions are utilized, hybridization will occur only with DNA sequences which have a high degree of complementarity with the probe. Thus, a low degree of stringency is desired to detect sequences with low complementarity, and the conditions may be varied accordingly. In general, the conditions may be as follows. The sodium ion concentration is about 1M, the pH about 5-9, the temperature about
20 65°C or about 20°C below the melting temperature of the duplex DNA of the probe sequence and its complementary strand (Britten, R. et al, *Methods in Enzymology* 29:363(1974); Sambrook et al, *supra*). The DNA-complementary polynucleotide labeled hybrid may be detected by methods known in the art. Typically, the double stranded DNA is restricted with enzymes and electrophoresed on a gel to separate the
25 different size fragments. The gel is blotted onto a specially prepared filter, hybridized, and the filter is then exposed to a photographic plate for an effective period of time. The plate is then developed and the different fragments analyzed. For a more qualitative detection of the presence of the double stranded labeled hybrid, the unrestricted DNA may be blotted onto a filter, hybridized, exposed to a photographic
30 plate and the plate developed to merely detect the presence of radiolabel.

The presence of an RNA sequence encoding the 46 Kdalton HMFG antigen or a fragment thereof may be determined by adding to a sample suspected of containing the RNA, a hybridization effective amount of the coding strand of a labeled polynucleotide encoding the 46 Kdalton HMFG hybrid polypeptide or fragment thereof
35 antigen in single stranded form under stringent conditions effective to hybridize any RNA having a complementary sequence of about at least 15 bases thereto, and

detecting the presence of the polynucleotide-RNA hybrid. In essence, this method is conducted as previously described for detection of a DNA sequence, with the additional precaution of substantially ensuring the absence of RNAses in the mixture. In general, the following must be additionally done when detecting RNA. The use of RNAase inhibitors and the pretreatment of labware with diethylpyrocarbonate to inactivate any contaminating RNAase. Hybridizations are conducted generally at a higher stringency because RNA:RNA hybrids are more stable than DNA:DNA hybrids. For example, the hybridization may be conducted at 65°C in 50% formamide. The T_m of DNA duplexes is reduced by about 0.72°C per 1% formamide added. (See, Sambrook et al, supra; Casey J. and Davidson N., Nucl. Acids Res. 4:1539-1552(1977)). If the RNA is contained inside the cells, the cells must be lysed to expose the ribonucleic acid. This is done by means known in the art such as detergent lysis, which may be followed by treatment with proteases.

Also part of this invention is a DNA segment comprising an anti-sense polynucleotide to the coding strand of the polynucleotide of the invention of about 200 to 1,800 nucleotides. More preferably, the DNA segment may have about 100 to 1,000 nucleotides. The concept of anti-sense sequences is generally known in the art. Synthetic oligonucleotides may be prepared that are complementary to the messenger RNA encoding a target protein. The oligonucleotide or a chemically modified equivalent thereof are then added to cells. The oligonucleotide binds the target mRNA and thus inhibits the translation of the target protein. (Markus-Sekura C.J., "Techniques for using Antisense Oligonucleotides to Study Gene Expression", Analytical Biochemistry 172:289-295(1988)). Alternatively, antisense-RNA may be used to block translation of sense RNA. The antisense RNA may be generated from a viral or plasmid DNA vector that contains a copy of the target gene situated in the reverse orientation with respect to the direction of transcription. A virus may be used as a carrier to introduce the inverted gene into the target cell genome. (Izant, J.G. and Weintmub H., Science 229:345-352(1985)). Fragments of the anti-sense DNA segment are also provided herein and they may comprise about 15 to 100 bases, and more preferably 30 to 50 bases. The anti-sense sequences may be obtained by methods known in the art such as the following. Antisense oligonucleotides can be made by modifying their phosphate moiety to increase biological lifetime, to enhance the permeability of the cells and to strengthen binding to the target. For example, oligomethylphosphonates (Miller, P.S., Reddy, M.P., Murakami, A., Blake, K.R., Lin, S.B. and Agris, C.H. (1986) Biochemistry 25:5092-5097), or oligophosphorothionates (LaPlanche, L.A., James, T.L., Powell, C., Wilson, W.D., Uznanski, B., Stec., W.J., Summers, M.F. and Zon, G.

(1986) Nucleic Acids Res. 14:9081-9093). Alternatively, the target gene may be inserted into a viral-based eukaryotic expression vector in reverse orientation and introduced into mammalian cells (See, Sambrook, J. et al, supra). The anti-sense DNA may be provided as a pharmaceutical composition which comprises in addition to the
5 anti-sense DNA or fragment thereof, a pharmaceutically-acceptable carrier. The composition may comprise different amounts of the components. Typically, the anti-sense DNA is contained in an amount of about 0.01 to 99.99 wt%, and more preferably about 0.1 to 20 wt% of the composition, the remainder being carrier and/or other known additives. The pharmaceutically-acceptable carrier may be any carrier
10 which does not degrade DNA and is physiologically tolerated. Examples of carriers and other additives are sterile buffered saline solution, human serum albumin and the like. However, others may also be utilized. The pharmaceutical composition may be prepared by admixing the anti-sense DNA with the carrier and other components as is known in the art, freeze dried and packaged in a sterile container. The composition
15 may be maintained refrigerated and/or frozen. The anti-sense product may be applied to the treatment of cancer of epithelial origin by administering it as a composition comprising a therapeutically effective amount of the anti-sense DNA segment of this invention or a fragment thereof. This method may be practiced by administering about 5 to 800 mg anti-sense DNA per day, and more preferably about 20 to 200 mg anti-
20 sense DNA per day in a pharmaceutical composition. The composition may be administered by a parenteral, intravenous, intracavitary or other localized route. However, other routes of administration may also be utilized.

Part of this invention is also an immunoassay kit comprising, in separate containers, a monoclonal antibody having specificity for the 46 Kdalton HMFG antigen
25 of this invention or Fab, (Fab)₂, or Fab' fragments thereof, anti-constant region immunoglobulin, protein G or A or binding fragments thereof for use with entire antibodies, and instructions for its use. This immunoassay kit may be utilized for practicing various of the methods provided herein. The monoclonal antibody and the anti-constant region immunoglobulin or other antibody binding molecules may be
30 provided in amounts of about 0.001 mg to 100 grams, and more preferably about 0.01 mg to 1 gram. The anti-constant region immunoglobulin and other antibody binding molecules may be a polyclonal immunoglobulin, protein A or protein G or functional fragments thereof, which may be labeled prior to use by methods known in the art. The antibody may also be provided as an immunotherapy kit, comprising in addition,
35 in separate containers, a therapeutic agent such as an anti-cancer agent and instructions for using the kit and for attaching either the therapeutic agent or a

radiolabel to the antibody or to a further component such as immunoglobulin, protein G or A or binding fragments thereof.

Also provided herein is an antibody detecting kit comprising, in separate containers, a polypeptide having the antibody binding specificity of the 46 Kdalton HMFG antigen, anti-constant region immunoglobulin, protein G or A or fragments thereof, and instructions for its use. The polypeptide may be a recombinantly obtained peptide and the anti-antibody immunoglobulin may be labeled prior to use. A fusion protein kit comprises, in separate containers, the fusion protein of this invention, an anti-second polypeptide monoclonal antibody, anti-constant region immunoglobulin, protein G or A or binding fragments thereof, and instructions for its use. The fusion protein may be provided in sterile form in an amount of about 0.001 mg to 100 grams, and more preferably about 0.01 mg to 1 gram. The anti-second polypeptide monoclonal antibody may also be provided in sterile form in an amount of about 0.001 mg to 100 grams, and more preferably about 0.01 mg to 1 gram. The anti-constant region immunoglobulin, protein G or A or fragments thereof may be provided in a separate sterile container in an amount of about 0.001 mg to 100 grams, and more preferably about 0.01 mg to 1 gram. The entire kit may be packaged for shipping and storage. An anti-cancer therapeutic kit provided according to this invention comprises, in separate containers, a monoclonal antibody selectively binding the 46 Kdalton HMFG antigen, an anti-cancer agent selected from the group consisting of immunotoxins and radionuclides and instructions for its use. The monoclonal antibody may be provided in sterile form in an amount of about 1 mg to 20 grams, and more preferably about 2 mg to 10 grams. The antibody may be freeze-dried and packaged and the therapeutic agent may be any known anti-cancer agent. By means of example, the agent may be abrin-A chain, ricin A-chain, immunotoxins, chemotherapy drugs, and ^{131}I and ^{90}Y radionuclides, among others.

Having now generally described this invention, the same will be better understood by reference to certain specific examples, which are included herein for purposes of illustration only and are not intended to be limiting of the invention or any embodiment thereof, unless so specified.

EXAMPLES

Example 1: Immunoscreening λ gt11 cDNA library

Two human breast cDNA libraries were purchased from Clontech (Palo Alto, CA). The first library was originally prepared from RNA extracted from adult breast tissue excised during mastectomy obtained during the 8th month of pregnancy and

showing well-differentiated tissue and lactational competence. The other cDNA library, ZR75, was reverse transcribed from mRNA extracted from the breast carcinoma cell line ZR75. The oligo-dT primed cDNA from this tissue was inserted into the Eco R1 site of λ gt11. Plating and screening of the library with monoclonal antibodies was
5 done essentially as described by Young and Davis (Young, R.A. and Davis, R.W., PNAS (U.S.A) 80:1194-1198 (1983)). The library was screened with a cocktail of monoclonal antibodies Mc3, Mc8, Mc15 and Mc16 all of which bind the 46 Kdalton component of human milk fat globule. (Peterson et al, Hybridoma (1990), supra; Larocca et al, Cancer Res. 51:4994 (1991)).

10 **Example 2:** **Blot Analysis**

The cell lines were grown to late log phase and total cell RNA prepared by the method of Chirgwin et al. (Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J., and Rutter, W.J. Biochemistry 18:5294-5299. (1979)). RNA was glyoxalated, electrophoresed, and blotted according to Thomas (Thomas, P., "Hybridization of
15 denatured RNA and small DNA fragments transferred to nitrocellulose", PNAS (USA) 77:5201-5205 (1980)) and RNA bound to nylon (Biodyne) filters using UV irradiation.

Single stranded RNA probes were made in vitro using SP6 and T7 RNA polymerase according to manufacturer (Promega) and labelled by incorporation of 32 P-UTP at 800 Ci/mmol (Amersham). Hybridization of RNA probes to RNA blots was at
20 70°C, 0.1 x SSC, 0.1% SDS. Blots were exposed to X-ray film (Kodak X-AR) at -80°C with intensifying screens.

Example 3: **DNA Sequencing**

Large scale bacteriophage DNA preparations were made from phage lysates, and the Eco R1 digested cDNA insert subcloned into pGEM3 (Promega, Madison, WI)
25 according to standard protocols (Sambrook, J., Fritsch, D., and Maniatis, T., in Molecular Cloning: A Laboratory Manual/Second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1990)). Dideoxy sequencing of the insert in pGEM3 was done with a modified T7 DNA polymerase (Sequenase) directly on the plasmid DNA using T7 or SP6 promoter sequence primers (Promega) according to the
30 manufacturer's protocol (USB, Cleveland, OH). The sequence was confirmed by repeatedly sequencing both strands of the insert.

Example 4: **Results**

15 positive plaques were selected after screening about 1×10^6 plaques from λ gt11 lactating breast cDNA library. The largest cDNA, BA46-1 was 1271 base pairs long. A series of positive λ gt11 clones were used to lysogenize Y1089 and the resulting fusion protein containing induced cell extracts were analyzed by dot blot
5 analysis for reactivity with each of the monoclonal antibodies contained in the screening cocktail.

It was found that monoclonal antibodies Mc8, Mc15 and Mc16 bound to all the positive λ gt11 lysogen extracts but not to the control λ gt11 extract (not shown). Monoclonal antibody Mc3, however, did not bind any of the lysates indicating that its
10 epitope requires either glycosylation, or secondary structure, or is not present in the library.

Example 5: Partial RNA Sequence

Single stranded RNA probes representing each strand of the BA46-1 cDNA insert were prepared by subcloning into Gem3 and transcribing in vitro with T7 or SP6
15 polymerase.

Several neoplastic tumor cell lines were studied including 5 breast lines and a lymphoid cell line of carcinomic origin for BA46-1 specific RNA. As shown in Figure 1 accompanying this patent, a single 2.2 kb RNA was detected in all cell lines tested. This RNA is also detectable in the Raji cell line, but at a much lower level that requires
20 longer exposures and it, therefore, does not appear in Figure 1.

There was considerable variation in the observed expression levels of the 2.2 kb RNA that were detected in the different cell lines. The lung (A549), ovary (SKOV3) and two breast (E11-G and HS578T) carcinoma cell lines accumulated from 10-50 fold more transcript than the other cell lines.

25 Example 6: Specificity Studies

Although the antibodies used to select the cDNA bound only to breast carcinomas by immunohistochemistry (Peterson et al, Hybridoma (1990), supra), expression of the 2.2 kb RNA fragment that encodes the 46 Kdalton HMFG antigen is expressed in many different cancer cell lines, such as carcinoma cell lines. The broad
30 specificity found for cancers from tissues of different origins, not only breast neoplastic cells may be attributed to a deregulation of this gene in neoplastic tumors such as carcinomas but not in normal tissue.

Normal epithelial tissue may also express the 46 Kdalton app. MW HMFG protein, but process it in a way that blocks the epitopes that are exposed in the breast

cell version of the protein by, for example, producing alterations in its glycosylation. The high molecular weight mucin-like protein of HMFG is also expressed in non-breast cancer cells such as carcinoma cells, but its altered processing in the pancreas, for example, leads to the exposure of different antigenic sites than in the breast (Lan, 5 M.S., Hollingworth, M.A., and Metzgar, T.S., Cancer Res. 50:2997 (1990)).

Example 7: Partial DNA Sequence

The nucleotide and derived amino acid sequence of BA46-1 cDNA is shown in Table 1 below.

Table 1: Partial DNA Sequence and Deduced Amino Acid Sequence of 46 Kdalton HMFG antigen

	*		10		*		20		*		30		*		40
GAT	TTC	ATC	CAT	GAT	GTT	AAT	AAA	AAA	CAC	AAG	GAG	TTT	GTG		
Asp	Phe	Ile	His	Asp	Val	Asn	Lys	Lys	His	Lys	Glu	Phe	Val		
	*		50		*		60		*		70		*		80
GGT	AAC	TGG	AAC	AAA	AAC	GCG	GTG	CAT	GTC	AAC	CTG	TTT	GAG		
Gly	Asn	Trp	Asn	Lys	Asn	Ala	Val	His	Val	Asn	Leu	Phe	Glu		
	*		90		*		100		*		110		*		120
ACC	CCT	GTG	GAG	GCT	CAG	TAC	GTG	AGA	TTG	TAC	CCC	ACG	AGC		
Thr	Pro	Val	Glu	Ala	Gln	Tyr	Val	Arg	Leu	Tyr	Pro	Thr	Ser		
		130		*		140		*		150		*		160	*
TGC	CAC	ACG	GCC	TGC	ACT	CTG	CGC	TTT	GAG	CTA	CTG	GGC	TGT		
Cys	His	Yhr	Ala	Cys	Thr	Leu	Arg	Phe	Glu	Leu	Leu	Gly	Cys		
		170		*		180		*		190		*		200	*
GAG	CTG	AAC	GGA	TGC	GCC	AAT	CCC	CTG	GGC	CTG	AAG	AAT	AAC		
Glu	Leu	Asn	Gly	Cys	Ala	Asn	Pro	Leu	Gly	Leu	Lys	<u>Asn</u>	<u>Asn</u>		
	*		220		*		230		*		240		*		250
AGC	ATC	CCT	GAC	AAG	CAG	ATC	ACG	GCC	TCC	AGC	AGC	TAC	AAG		
<u>Ser</u>	Ile	Pro	Asp	Lys	Gln	Ile	Thr	Ala	Ser	Ser	Ser	Tyr	Lys		
	*		260		*		270		*		280		*		290
ACC	TGG	GGC	TTG	CAT	CTC	TTC	AGC	TGG	AAC	CCC	TCC	TAT	GCA		
Thr	Trp	Gly	Leu	His	Leu	Phe	Ser	Trp	Asn	Pro	Ser	Tyr	Ala		
	*		300		*		310		*		320		*		330
CGG	CTG	GAC	AAG	CAG	GGC	AAC	TTC	AAC	GCC	TGG	GTT	GCG	GGG		
Arg	Leu	Asp	Lys	Gln	Gly	Asn	Phe	Asn	Ala	Trp	Val	Ala	Gly		
		340		*		350		*		360		*		370	*
AGC	TAC	GGT	AAC	GAT	CAG	TGG	CTG	CAG	GTG	GAC	CTG	GGC	TCC		
Ser	Tyr	Gly	Asn	Asp	Gln	Trp	Leu	Gln	Val	Asp	Leu	Gly	Ser		

Table 1: Partial DNA Sequence and Deduced Amino Acid Sequence of 46 Kdalton HMFG Antigen (Cont'd.)

380	*	390	*	400	*	410	*	420					
TCG	AAG	GAG	GTG	ACA	GGC	ATC	ATC	ACC	CAG	GGG	GCC	CGT	AAC
Ser	Lys	Glu	Val	Thr	Gly	Ile	Ile	Thr	Gln	Gly	Ala	Arg	Asn
	*	430	*	440	*	450	*	460					
TTT	GGC	TCT	GTG	CAG	TTT	GTG	GCA	TCC	TAC	AAG	GTT	GCC	TAC
Phe	Gly	Ser	Val	Gln	Phe	Val	Ala	Ser	Tyr	Lys	Val	Ala	Tyr
	*	470	*	480	*	490	*	500					
AGT	AAT	GAC	AGT	GCG	AAC	TGG	ACT	GAG	TAC	CAG	GAC	CCC	AGG
Ser	<u>Asn</u>	<u>Asp</u>	<u>Ser</u>	Ala	<u>Asn</u>	<u>Trp</u>	<u>Thr</u>	Glu	Tyr	Gln	Asp	Pro	Arg
	*	510	*	520	*	530	*	540	*				
ACT	GGC	AGC	AGT	AAG	ATC	TTC	CCT	GGC	AAC	TGG	GAC	AAC	CAC
Thr	Gly	Ser	Ser	Lys	Ile	Phe	Pro	Gly	Asn	Trp	Asp	<u>Asn</u>	<u>His</u>
	*	550	*	560	*	570	*	580	*				
TCC	CAC	AAG	AAG	AAC	TTG	TTT	GAG	ACG	CCC	ATC	CTG	GCT	CGC
<u>Ser</u>	His	Lys	Lys	Asn	Leu	Phe	Glu	Thr	Pro	Ile	Leu	Ala	Arg
	*	590	*	600	*	610	*	620	*	630			
TAT	GTG	CGC	ATC	CTG	CCT	GTA	GCC	TGG	CAC	AAC	CGC	ATC	GCC
Tyr	Val	Arg	Ile	Leu	Pro	Val	Ala	Trp	His	Asn	Arg	Ile	Ala
	*	640	*	650	*	660	*	670					
CTG	CGC	CTG	GAG	CTG	CTG	GGC	TGT	TAG	TGG	CCA	CCT	GCC	ACC
Leu	Arg	Leu	Glu	Leu	Leu	Gly	Cys	End	(■)				
	*	680	*	690	*	700	*	710					
CCC	AGG	TCT	TCC	TGC	TTT	CCA	TGG	GCC	CGC	TGC	CTC	TTG	GCT
	*	720	*	730	*	740	*	750	*				
TCT	CAG	CCC	CTT	TAA	ATC	ACC	ATA	GGG	CTG	GGG	ACT	GGG	GAA
	*	760	*	770	*	780	*	790	*				
GGG	GAG	GGT	GTT	CAG	AGG	CAG	CAC	CAC	ACA	GTC	ACC	CCT	
	*	800	*	810	*	820	*	830	*	840			
CCC	TCC	CTC	TTT	CCC	ACC	CTC	CAC	CTC	TCA	CGG	GCC	CTG	CCC
	*	850	*	860	*	870	*	880					
CAG	CCC	CTA	AGC	CCC	GTC	CCC	TAA	CCC	CCA	GTC	CTC	ACT	GTC
	*	890	*	900	*	910	*	920					
CTG	TTT	TCT	TAG	GCA	CTG	AGG	GAT	CTG	AGT	AGG	TCT	GGG	ATG
	*	930	*	940	*	950	*	960	*				
GAC	AGG	AAA	GGG	CAA	AGT	AGG	GCG	TGT	GGT	TTC	CCT	GCC	CCT

Table 1: Partial DNA Sequence and Deduced Amino Acid Sequence of 46 Kdalton HMFG Antigen (Cont'd.)

970	*	980	*	990	*	1000	*						
GTC	CGG	ACC	GCC	GAT	CCC	AGG	TGC	GTG	TGT	CTC	TGT	CTC	TCC
1010	*	1020	*	1030	*	1040	*	1050					
TAG	CCC	CTC	TCT	CAC	ACA	TCA	CAT	TCC	CAT	GGT	GGC	CTC	AAG
*	1060	*	1070	*	1080	*	1090						
AAA	GGC	CCG	GAA	GCC	CCA	GGC	TGG	AGA	TAA	CAG	CCT	CTT	GCC
*	1100	*	1110	*	1120	*	1130						
CGT	CGG	CCC	TGC	GTC	GGC	CCT	GGG	GTA	CCA	TGT	GCC	ACA	ACT
*	1140	*	1150	*	1160	*	1170	*					
GCT	GTG	GCC	CCC	TGT	CCC	CAA	GAC	ACT	TCC	CCT	TGT	CTC	CCT
1180	*	1190	*	1200	*	1210	*						
GGT	TGC	CTC	TCT	TGC	CCC	TTG	TCC	TGA	AGC	CCA	GCG	ACA	CAG
1220	*	1230	*	1240	*	1250	*	1260					
AAG	GGG	GTG	GGG	CGG	GTC	TAT	GGG	GAG	AAA	GGG	AGC	GAG	GTC
*	1270	*	1280	*	1290	*	1300						
AGA	GGA	GGG	CAT	GGG	TTG	GCA	GGG	TGG	GCG	TTT	GGG	GCC	CTC
*	1310	*	1320	*	1330	*	1340						
ATG	CTG	GCT	TTT	CAC	CCC	AGA	GGA	CAC	AGG	CAG	CTT	CCA	AAA
*	1350	*	1360	*	1370	*	1380						
TAT	ATT	TAT	CTT	CTT	CAC	GGG	AAA	AAA	AAA	AAA	AAA	ACC	G (□)

(□): SEQ. ID. No. 1

(■): SEQ. ID. No. 2

Potential n-linked glycosylation sites are underlined

The partial ORF sequence is 217 amino acids long and compounds to a theoretical molecular weight of about 24 Kdalton, representing the C-terminus of the complete protein. There are four potential sites for n-linked glycosylation and the polypeptide sequence is asparagine and leucine rich.

Example 8: Homology to Clotting Factors

A comparison of the nucleotide sequence to the EMBL database using FSTNSCAN (PCGENE) revealed extended homology with human serum factors V and VIII and protein C. The partial deduced protein sequence, however, shares identity only with factors V and VIII but not with protein C since the homology at the nucleotide

level is found in an intervening sequence (See, Table 2 below).

Table 2: Comparison of Deduced BA46-1 Amino Acid Sequence with C-terminal Human Serum Factors V and VIII

46 Kdalton	F I H D V N K K H K E F V G N W N K N A V H V N
FAV	F K G N S T R N V M Y F N G N S D A S T I K E N
FAVIII	Y R G N S T G T L M V F F G N V D S S G I K H N
	L F E T P V E A Q Y V R L Y P T S C H T A C T L R F E L
	Q F D P P I V A R Y I R I S P T R A Y N R P T L R L E L
	I F N P P I I A R Y I R L H P T H Y S I R S T L R M E L
	L G C E L N G C A N P L G L K N N S I P D K Q I T A S S
	Q G C E V N G C S T P L G M E N G K I E N K Q I T A S S
	M G C D L N S C S M P L G M E S K A I S D A Q I T A S S
	S Y K T W G L H L F S W N P S Y A R L D K Q G N F N A W
	F K K S W W G D Y - - W E P F R A R L N A Q G R V N A W
	Y F T N M F A T - - - W S P S K A R L H L Q G R S N A W
	V A G S Y G N D Q W L Q V D L G S S K E V T G I I T Q G
	Q A K A N N N K Q W L E I D L L K I K K I T A I I T Q G
	R P Q V N N P K E W L Q V D F Q K T M K V T G V T T Q G
	A R N F G S V Q F V A S Y K V A Y S N D S A N W T E Y Q
	C K S L S S E M Y V K S Y T I H Y S E Q G V E W K P Y R
	V K S L L T E M Y V K E F L I S S S Q D G H Q W T L F F
	D P R T G S S K I F P G N W D N H S H K K N L F E T P I
	L K S S M V D K I F E G N T N T K G H V K N F F N P P I
	Q N - - G K V K V F Q G N Q D S F T P V V N S L D P P L
	L A R Y V R I L P V A W H N R I A L R L E L L G C
	I S R F I R V I P K T W N Q S I A L R L E L F G C D - -
	L T R Y L R I H P Q S W V H Q I A L R M E V L G C E A Q
	(SEQ. ID. No. 3)
- I Y	(SEQ. ID. No. 4)
D L Y	(SEQ. ID. No. 5)

An arrow indicates function of C and C2 repeats

There is about 43% identity of BA46 to Factor V and about 38% to factor VIII. The region of factors V and VIII in Table 2 share about 47% identity.

Example 9: Amino Acid Sequence

The analysis of the derived amino acid sequence of the 46 Kdalton app. MW protein is consistent with its description as a glycosylated protein containing four N-linked glycosylation sites. Since the 46 Kdalton app. MW protein has homology to both factors V and VIII, there may be a common ancestral protein to these serum clotting factors. The homology is in the C1C2 region of the light chain of factor VIII (Arai, M., Scandella, D., and Hoyer, L.W., J. Clin. Invest. 83:1978-1984 (1989)).

Arai et al have shown that human antibodies that bind the C1C2 region of the light chain from hemophiliacs treated with factor VIII inhibit factor VIII by preventing the interaction of factor VIII with phospholipids and that it is implicated in phospholipid binding. It is likely that the similar sequence is also important for phospholipid binding
5 in the 46 Kdalton glycoprotein.

The C-terminal portion could serve as a novel "anchor" sequence for the 46 Kdalton app. MW protein or it could be involved in the binding of the mucin/membrane to the phospholipids on the surface of the growing milk fat droplet (Long, C.A., and Patton, S., J. Dairy Sci. 61:1392-1399 (1978)). It could also be involved in the
10 assembly of the mucin complex at the plasma membrane surface.

Example 10: Screening of cDNA Libraries

The ZR75 λ gt11 cDNA library was screened using an isolated cloned LB21 sequence encompassing bases 562 through 1838 of the total 1934 base pairs of the 46 Kdalton app. MW BA46 clone and labeled with P^{32} using random primers. The
15 cDNA clone LB21 utilized herein comprises a portion of the C-terminal region of the BA46 cDNA, and its cloning and expression in E. coli as an expression vector (pEX/LB21) have been described by Larocca, et al (Larocca et al, Molecular Cloning and Expression of Breast Mucin-associated Antigens", in Breast Epithelial Antigens: Molecular Biology to Clinical Applications, Ceriani R.L. Ed., PP. 35-44, New York
20 Plenum Press (1991)). The bacteriophages were plated at a density of 30,000 pfu / 150 mm plates with E. coli Y1090, and blotted with nitrocellulose filters as described by Larocca et al. (Larocca et al, "Cloning and sequencing of a complementary DNA encoding a Mr 70, 000 human breast epithelial mucin-associated antigen", Cancer Res. 50:5925-5930 (1990)). The P^{32} -labeled LB21 clones were then screened, and
25 positive plaques visualized by autoradiography, picked and plaque purified. The inserts were amplified by PCR using forward and reverse primers for the adjacent λ gt11 bacteriophage sequences, subcloned into pGEM3 (Promega, Madison, WI) at the EcoR1 site, and sequenced by the Sanger method of dideoxynucleotide chain termination as described by Larocca et al, "Cloning and sequencing of a complementary DNA
30 encoding a Mr 70, 000 human breast epithelial mucin-associated antigen", (Cancer Res. 50:5925-5930 (1990); Sanger et al, "DNA sequencing with chain-terminating inhibitors", PNAS (USA) 74:463-5467 (1977)). The screening of the human breast λ gt11 cDNA library was done by PCR using an up-stream primer for the λ gt11 vector and several downstream primers for known sequences in the 5' region.

Example 11: PCR Primer Synthesis

The primers listed in Table 3 below were synthesized for the PCR using an Applied Biosystems model 391 PCR-MATE DNA synthesizer by the phosphoramidite method. The oligonucleotides were run on a 8M urea/10% polyacrylamide denaturing gel to assess their purity and integrity.

Table 3: DNA Sequence of Primers Utilized

Primer	Type [*]	DNA Sequence
5'-46KRT'	Antisense	5'-GGTGTCCAGGCATTGACCAT-3'
BA46 P-2 [□]	Antisense	5'-GCTGCAAACCCAAGAAGGTCAC-3'
BA46 P-A [†]	Antisense	5'-TAAGGCACGTGCAGGTGTACGA-3'
BA46P-C	Antisense	5'-TTGGAACAGATATCCAGGGCGA-3'
λgt11 Fwd.	Sense	5'-GGTGGCGACGACTCCTGGAGCCCG-3'
λgt11 Rev.	Sense	5'-TTGACACCAGACCAACTGGTAATG-3'

* Sense or antisense indicates the sequence of the primer is either identical or complementary to the BA46 mRNA, respectively.

^{*} Bases 337-356 of the M, 46,000 gene coding sequence.

[□] Bases 277-298 of the M, 46,000 gene coding sequence.

[†] Bases 154-175 of the M, 46,000 gene coding sequence.

Bases 65-86 of the M, 46,000 gene coding sequence.

Example 12: PCR Conditions

The PCR was carried out in a 50 ml reaction volume using the GeneAmp PCR kit (Perkin Elmer Cetus, CT). The samples were run under "hot start" conditions, in 0.2 ml PCR MicroAmp[™] tubes using the GeneAmp[™] PCR system 9600 (Perkin Elmer-Cetus, CT). The following conditions were used for PCR screening of the human breast cDNA library. In each tube, 5 μ l of a 1:10 dilution of the cDNA library (equivalent to approximately 0.65×10^6 independent cell clones) were added to 40 μ l PCR master reaction mixture containing 5 μ l of 10 x PCR buffer II (100 mM Tris-HCl, pH 8.3, 500 mM KCl), 4 μ l of 25 mM MgCl₂, 1 μ l each of 10 mM dNTP, 17 μ l sterile water, 5 μ l of 2 mM (M_o = 46,000) gene specific antisense primer, and 5 μ l of 2 mM λgt11 sense primer. The samples were heated to 95°C for 2 min in the PCR system 9600, allowed to cool to 75°C and held at this temperature while 1.25 units of "AmpliTaq" DNA polymerase were added in 5 μ l of 1 x Taq buffer. Primer annealing was initially performed at 62°C for 30 sec followed by 35 cycles of denaturation at

95°C, ramping to 64°C in 30 sec and annealing and extending at 64°C for 30 sec. After completion of the PCR cycles, the reaction mixtures were extended at 72°C for 7 min and cooled to 4°C.

The amplified DNA was subjected to gel electrophoresis, ethidium bromide
5 stained, and visualized under UV light. A smear of DNA bands relating to incomplete
5'-ends of the BA46 cDNA was cloned directly into pCR™ II using a TA cloning kit
from Invitrogen (San Diego, CA). This method took advantage of the non-template
dependent activity of Taq polymerase that adds a single dA to the 3' end of PCR
duplex products (Marchuck et al, "Nucleic Acids Res. 19:1154 (1991)). Single 3'dT
10 overhangs in the vector, pCR™ II, allowed for PCR product insertion.

Example 13: Nucleotide sequencing

The cDNA clones isolated from the screening of the ZR75 breast cell λ gt11
cDNA library were subcloned into a pGEM3 plasmid and sequenced by the
15 dideoxynucleotide chain termination method as described by Larocca et al. (Larocca, et
al, "Cloning and sequencing of a complementary DNA encoding a M, 70,000 human
breast epithelial mucin-associated antigen", Cancer Res. 50:5925 (1990)). Positive
clones obtained from the human breast library by the PCR method were picked,
amplified and phage DNA isolated by the method of lysis by boiling as described by
20 Sambrook et al. (Sambrook et al, in Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor, Cold Spring Harbor Press (1989)). EcoR1 digested inserts were
screened by gel electrophoresis choosing DNA fragments of the size expected. The
size of the chosen DNA fragments was assessed from the fact that a single 2.2
kilobase RNA was detected in carcinoma cell lines, by Northern blotting as described
25 above (Larocca et al., "A 46 Kdalton human milk fat globule glycoprotein that is highly
expressed in carcinoma cells has homology with human clotting factors V and VIII",
Cancer Res. 51:4994 (1991)).

High yields of pure supercoiled plasmid DNA for sequencing were prepared from
overnight cultures of selected clones using the Qiagen plasmid miniprep kit
30 (Qiagen Inc., CA). The insert in pCR™ II was sequenced by the method of
dideoxynucleotide chain termination (Sanger, supra), using a modified T7 DNA
polymerase (Sequenase Version 2.0) under the conditions recommended by the supplier
(USB Corp., Cleveland, OH). Both strands were sequenced by priming in the plasmid
with either M13 reverse or M13 (-40) forward primers (USB Corp., OH). The analysis
35 of the sequence was performed using GeneWorks software (IntelliGenetics, Inc.,
Mountain View, CA).

The breast cDNA library was screened by PCR, priming with the λ gt11 Fwd. and the BA46 P-2 primers described above. The latter primer comprises bases 277-298, 37 bases within the 5' end of the sequence obtained by screening the ZR75 library and provided an extra 197 bases of the 5' end of the M_r = 46,000 cDNA. A second BA46 gene specific primer (BA46 P-A, bases 154-175) was synthesized within the extended 5' end sequence and used to further screen the breast cDNA library. The BA46 cDNA was further extended by 43 bases including the start codon.

Example 14: Confirmation of 5' end of BA 46 cDNA

The 5'-end of the 46 Kdalton BA46 cDNA was confirmed by screening mRNA from a breast cell line using the 5'-AmpliFinder RACE kit (Clontech, Palo Alto). PolyA⁺ RNA was prepared from the "ELL-G" breast cell line using a "FastTrack mRNA isolation kit, version 3.2" (Invitrogen, San Diego, CA). cDNA was synthesized from 2 μ g of the ELL-G mRNA using the antisense gene specific primer "5'-46KRT" (bases 337-356) with the 5'-AmpliFinder RACE kit. The RNA template was then hydrolyzed with NaOH, and the cDNA purified by binding to a glass matrix support (GENO-BINDTM particles) in preparation for the ligation of a single stranded anchor oligonucleotide to the 3' end of the cDNA. The gene was then amplified by PCR using the nested antisense gene-specific primers "BA46 P-A and BA46 P-C" and a primer complementary to the anchor. PCR was carried out as described above under "hot start" conditions using AmpliTaq DNA polymerase, Stoffel fragment (Perkin Elmer-Cetus). Each 50 μ l of PCR reaction mixture contained a 1:100 dilution of the anchor ligation mix, 1 x Stoffel buffer (10 mM KCl, 10 mM Tris HCl, pH 8.3), 3 mM MgCl₂, 0.2 mM each of dNTP and 0.3 μ M of sense and antisense (both) primers.

The samples were heated to 98°C for 1 min, cooled to 75°C, and 5 units of the Stoffel fragment added. The primers were initially annealed and extended at 64°C for 30 seconds. Two PCR methods were used to amplify the gene. The first consisted of 10 cycles of denaturing at 97°C for 10 seconds and annealing and extending at 62°C for 25 seconds. This was followed by 30 cycles of denaturing at 95°C for 10 seconds and annealing and extending at 60°C for 25 seconds. A final extension at 72°C for 7 min ensured that all the templates were completed. The PCR products were visualized on a 2% agarose gel, and then cloned into the pCR II vector (TA cloning kit, Invitrogen) for dideoxynucleotide sequencing.

**Example 15: Complete DNA Sequence of Polynucleotide
Encoding 46 Kdalton HMFG Antigen**

The partial cDNA sequence for the 46 Kdalton HMFG antigen clone (BA46) provided in Example 7 above was completed. A complete DNA sequence was obtained by screening and PCR amplification of a cDNA library, and the rapid amplification of cDNA ends (RACE) method. The breast carcinoma cell line ZR75 cDNA library was screened with the partial cDNA clone LB21 of the BA46 sequence shown above, and labeled with P³².

Two new cDNA clones were isolated, which provided further information on the cDNA segment encoding the 46 Kdalton HMFG antigen. These two clones completed the 3' end (97 bases to the polyadenylation site), and extended by 267 bases the 5' end of the cDNA sequence.

The sequence of the 5' end of the cDNA was completed by screening a human breast λ gt11 cDNA by PCR amplification using antisense primers on the 5' end of the BA46 cDNA, and sense primers within the λ gt11 cloning vector. The latter PCR method allowed the complete sequencing of the open reading frame (ORF) of the 46 Kdalton HMFG polypeptide (BA46) cDNA. The ORF sequence was confirmed and the non-coding 5' end was sequenced by the RACE method. Each cDNA insert was sequenced in both directions on at least two independent isolates to verify the sequence.

The entire cDNA contains 1934 bases and an ORF 1161 nucleotides encoding 387 nucleotides as shown in Table 4 below.

**Table 4: Complete DNA Sequence Encoding the 46 Kdalton
HMFG Antigen & Deduced Amino Acid Sequence**

1	AGAACCCCGCGGGTCTGAGCAGCCCAGCGTGCCCATTCAGCGCCCGCGTCCCCGCAGC
61	ATGCCGCGCCCCCGCCTGCTGGCCGCGCTGTGCGGCGCGCTGCTCTGCGCCCCCAGCCTC
1	M P R P R L L A A L C G A L L C A P S L
121	CTCGTCGCCCTGGATATCTGTTCCAAAACCCCTGCCACAACGGTGGTTTATGCGAGGAG
21	L V A L D I C S K N P C H N G G L C E E
181	ATTTCCCAAGAAGTGCGAGGAGATGTCTTCCCTCGTACACCTGCACGTGCCTTAAGGGC
41	I S Q E V R G D V F P S Y T C T C L K G
241	TACGCGGGCAACCACTGTGAGACGAAATGTGTGAGCCACTGGGCATGGAGAATGGGAAC
61	Y A G N H C E T K C V E P L G M E N G N
301	ATTGCCAACTCACAGATCGCCGCCTCATCTGTGCGTGTGACCTTCTTGGGTTTGCAGCAT
81	I A N S Q I A A S S V R V T F L G L Q H
361	TGGGTCCCGGAGCTGGCCCGCCTGAACCGCGCAGGCATGGTCAATGCCTGGACACCCAGC
101	W V P E L A R L N R A G M V N A W T P S

Table 4: Complete DNA Sequence Encoding the 46 Kdalton
HMFG Antigen & Deduced Amino Acid Sequence (Cont'd)

```

421 AGCAATGACGATAACCCCTGGATCCAGGTGAACCTGCTGCGGAGGATGTGGGTAACAGGT
121 S N D D N P W I Q V N L L R R M W V T G

481 GTGGTGACGCAGGGTGCCAGCCGCTTGCCAGTCATGAGTACCTGAAGGCCTTCAAGGTG
141 V V T Q G A S R L A S H E Y L K A F K V

541 GCCTACAGCCTTAATGGACACGAATTTCGATTTCATCCATGATGTTAATAAAAAACACAAG
161 A Y S L N G H E F D F I H D V N K K H K

601 GAGTTTGTGGGTAACCTGGAACAAAAACGCGGTGCATGTCAACCTGTTTGAGACCCCTGTG
181 E F V G N W N K N A V H V N L F E T P V

661 GAGGCTCAGTACGTGAGATTGTACCCACGAGCTGCCACACGGCCTGCACTCTGCGCTTT
201 E A Q Y V R L Y P T S C H T A C T L R F

721 GAGCTACTGGGCTGTGAGCTGAACGGATGCGCCAATCCCCTGGGCCTGAAGAATAACAGC
221 E L L G C E L N G C A N P L G L K N N S

781 ATCCCTGACAAGCAGATCACGGCCTCCAGCAGCTACAAGACCTGGGGCTTGCATCTCTTC
241 I P D K Q I T A S S S Y K T W G L H L F

841 AGCTGGAACCCCTCCTATGCACGGCTGGACAAGCAGGGCAACTTCAACGCCTGGGTTGCG
261 S W N P S Y A R L D K Q G N F N A W V A

901 GGGAGCTACGGTAACGATCAGTGGCTGCAGGTGGACCTGGGCTCCTCGAAGGAGGTGACA
281 G S Y G N D Q W L Q V D L G S S K E V T

961 GGCATCATCACCCAGGGGGCCGTAACCTTTGGCTCTGTCCAGTTTGTGGCATCCTACAAG
301 G I I T Q G A R N F G S V Q F V A S Y K

1021 GTTGCCTACAGTAATGACAGTGCGAAGTGGACTGAGTACCAGGACCCAGGACTGGCAGC
321 V A Y S N D S A N W T E Y Q D P R T G S

1081 AGTAAGATCTTCCCTGGCAACTGGGACAACCACTCCCAAGAAGAAGTGTGTTGAGACG
341 S K I F P G N W D N H S H K K N L F E T

1141 CCCATCCTGGCTCGCTATGTGCGCATCCTGCCTGTAGCCTGGCACAACCGCATCGCCCTG
361 P I L A R Y V R I L P V A W H N R I A L

1201 CGCCTGGAGCTGCTGGGCTGTTAGTGGCCACCTGCCACCCCAAGTCTTCCTGCTTTCCA
381 R L E L L G C (SEQ. ID No: 6)

1261 TGGGCCCGCTGCCTCTTGGCTTCTCAGCCCCCTTTAAATCACCATAGGGCTGGGGACTGGG
1321 GAAGGGGAGGGTGTTTCAGAGGCAGCACCACCACACAGTCACCCCTCCCTCCCTCTTTCCC
1381 ACCCTCCACCTCTCACGGGCCCTGCCCCAGCCCCCTAAGCCCCGTCCCCTAACCCCCAGTC
1441 CTCACCTGCTCTGTTTCTTAGGCACTGAGGGATCTGAGTAGGTCTGGGATGGACAGGAAA
1501 GGGCAAAGTAGGGCGTGTGGTTTCCCTGCCCCCTGTCCGGACCGCGATCCCAGGTGCGTG
1561 TGTCTCTGTCTCTCCTAGCCCCCTCTCTCACACATCACATCCCATGGTGGCCTCAAGAAA
1621 GGCCCGGAAGCCCCAGGCTGGAGATAACAGCCTCTTGCCCGTGGGCCCTGCGTGGGCCCT
1681 GGGGTACCATGTGCCACAAGTGTGTGGCCCCCTGTCCCAAGACACTTCCCTTGTCTC
1741 CCTGGTTGCTCTCTTGGCCCCCTGTCTCTGAAGCCAGCGACACAGAAGGGGGTGGGGCGG
1801 GTCTATGGGGAGAAAGGGAGCGAGGTGAGAGGAGCCGGCATGGGTTGGCAGGGTGGGCGT
1861 TTGGGGCCCTCATGCTGGCTTTTACCCCAAGGACACAGGCAGCTTCCAAAATATATTT
1921 ATCTTCTTCACGGG (SEQ. ID No: 7)

```

The cDNA sequence is characterized by a 3' poly(A) tail and an untranslated 3' region of 713 nucleotides. The usual consensus polyadenylation signal sequence of AATAAA is not found but the sequence AATATA is found in the same position relative to the AATACA sequence found in the mouse MFGE8 cDNA sequence, 17 nucleotides upstream of the poly(A) tail (Stubbs et al., "cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences", PNAS (USA) 87:8417-8421 (1990)). The AATACA and AATATA sequences are considered alternate polyadenylation signals. At the 5' end of the cDNA, the first ATG start codon is preceded by the sequence GCAGC, which is frequently associated with AGT start codons. The non-coding 5' region contains 60 nucleotides.

15 The BA46 cDNA sequence has considerable homology with the cDNA of a mouse milk fat globule glycoprotein MFGE8 of 66/55 Kdalton described by Stubbs et al, supra. The nucleotide sequence of the BA46 open reading frame has 76% identity with that of MFGE8. The 5' and 3' non-coding regions have 71% and 62% identities, respectively. The greatest % identity is present in the nucleotide sequences encoding
20 the function domains, within the open reading frame, that are shared by the two encoded proteins as shown in Table 5 below.

```

46KORF      - MPRPRLLAALCGALLCAPSLLVLD----- -25
              :  :.:::  :  :  :
MFG88PRO    - MQVSRYLAALCGMLLCASGLFAASGDFCDSSLCLNGGTCLTGQDNDIYCLCPBGP-like -55

46KORF      - -----ICSKNPCHNGGLCBEISQSVRGDVPFSTYCTCLKYAGNHCST- -68
              :  :  :  :  :  :  :  :  :  :  :  :  :
MFG88PRO    - TGLVCNETERGPGSPNCPYNDACLVLDTQGRGDIPTYICQCPVGYSGIHCEB- -110

46KORF      - -----KCEPLGMHENGNIANSQIA- -87
              :  :  :  :  :  :
MFG88PRO    - TNYYNLDGBYHFTTAVPNTAVPTPAPTDLNNLASRCSTQLGMEGGAIADSQIS- -165

46KORF      - ASSVRVTFGLQHWVPLSLRLNRAGMVNAWTFSSNDNPWIQVNLRRMWTGVV- -142
              :  :  :  :.:::  :  :  :  :  :  :  :  :  :  :  :  :  :
MFG88PRO    - ASYVVMGPMGLQRWGPELRLRYRTGIVNAWHASNYDSLPIQVNLRLKMRVSGVM- -220

46KORF      - TQGSARSLASHEYLKAFKAVAYSLNGHEPFDIHDVNMQCHKBPVGNWNKNQAVHVNLPB- -197
              :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
MFG88PRO    - TQGASRAGRAYSLYKTFKAVAYSLDGRKFETIQDESGGDKBFLGNLDNLSLKVNMFN- -275

```

Table 5: Homologies between 46 Kdalton HMFG Antigen Polypeptide and MMFG Antigen Polypeptide (MFGE8) (Cont'd)

46KORF	-	TPVEAQYVRLYPTSCHTACTLRFELLGCBLNGCANPLGLKNNIPDKQITASSSY	-252
		
MFGE8PRO	-	PTLEAAYIRLYPVSCHRGCTLRFELLGCBLHGCLFPLGLKNTIPDSQMSASSSY	-330
46KORF	-	KTWGLHLFSWNPYSYARLDKQGNFNWVAGSYGNDQWLQVDLGSSKEVTGIITQGA	-307
		
MFGE8PRO	-	KTWNLRAPFGWYPHLGRLDNQKINAWTAQNSAKEWLQVDLGTQRQVTGIITQGA	-385
46KORF	-	RNFGSVQFVASYKVAYSNDSANWTEYQDPRTGSSKIFPGNWDNHSKGNLFETPI	-362
		
MFGE8PRO	-	RDFGHIQYVESYKVAHSDDGQVQWTVYBEQ--GSSKVFQGNLDNNSHKGNIFEKPF	-438
46KORF	-	LARYVRILPVAWHNRIRLRLELLGC	-387
		
MFGE8PRO	-	MARKVRVLPVSWHNRITLRLELLGC	-463

* (SEQ. ID No: 8)

+ (SEQ. ID No: 9)

. Similar Amino Acid

: Identical Amino Acid

Example 18: Epitope mapping

Overlapping peptide hexamers spanning amino acids 330-382 of the 46 Kdalton HMFG polypeptide (BA46) sequence were synthesized onto the ends of polyethylene pins using an Epitope Scanning Kit (Cambridge Research Biochemicals, Cambridge, UK) as described by Geysen et al. (Geysen, et al. "Use of a peptide synthesis to probe vital antigens for epitopes to a resolution of a single amino acid", PNAS (USA) 81:3998-4002 (1984)). The polyethylene pins are arranged in an 8 x 12 configuration that fit into a 96 well microliter dish and were supplied with a β -alanine attached to the ends to which the amino acids are added, consecutively using pentafluorophenyl active esters of fluorenylmethyloxycarbonyl (Fmoc)-L-amino acids. Each consecutive overlapping hexamer or octamer differed from the previous one by a single amino acid and were synthesized to span amino acids 330-382 of the BA46 peptide so that every combination of hexamer or octamer was present. The binding of monoclonal antibodies Mc3, Mc8, Mc15, Mc16 raised against the BA46 antigen as described by Peterson et al (Peterson et al., "Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule", Hybridoma 9:221-235 (1990)) to the synthetic peptides was tested using the ELISA method with horse radish peroxidase-conjugated goat anti-mouse IgG (Promega, Madison, WI), and color development with 2,2' azino bis (3-ethyl benzothiazidine-6-

sulfuric acid (Sigma, St. Louis, MO).

Example 19: Open Reading Frame and Antibody Binding Characteristics

The largest open reading frame of the BA46 cDNA encodes a protein of 387 amino acids with an estimated molecular weight of 43,123 Kdalton s. The actual correspondence of the cDNA cloned to the BA46 glycoprotein antigen isolated from the HMFG was shown by the correlation of the BA46 mRNA with the expression to the BA46 antigen in different breast cell lines (Larocca et al., "A 46 Kdalton human milk fat globule glycoprotein that is highly expressed in carcinoma cells has homology with human clotting factors V and VIII", Cancer Res. 51: 994 (1991)) and the binding of the monoclonal antibodies used to in the cDNA screening to the pEX/LB21 fusion protein expressed in E. coli (Larocca et al., "Molecular cloning and expression of breast mucin-associated antigens", in Breast Epithelial Antigens: Molecular Biology to Clinical Applications, R.L. Ceriani, Ed., pp. 35-44, New York Plenum Press (1991)). In addition, 5 defined and distinct amino acid sequence epitopes in the C-terminal end of the protein were determined by epitope mapping for two monoclonal antibodies of the cocktail used in the original screening of the cDNA library (Mc8 = DPRTG; and Mc16 = SSKIF) (See, Table 4 above). The two other monoclonal antibodies (Mc3, Mc15) neither bind to the pEX/LB21 fusion protein nor to any of the peptide hexamers used in the epitope mapping of the C-terminal region (amino acids 330 - 382) of the 46 Kdalton polypeptide.

Example 20: Homology of 46 Kdalton Polypeptide (BA46) with Other Known Proteins

The amino acid sequence deduced with the help of the PC/GENE DNA and the protein analysis program (IntelliGenetics, Inc.) revealed the existence of homologies with several functional domains. At the N-terminal end, there is a hydrophobic region after the Met start codon which most likely corresponds to a signal peptide. Cleavage most likely occurs between the val₂₁ and ala₂₂, leaving a cleaved peptide of 21 amino acids plus the methionine. This cleavage results in a processed polypeptide of 40,862 Kdalton s. Amino acids 46 to 48 represent a known cell adhesion sequence (RGD), and following this is an EGF-like domain (amino acids 55 to 66). The C-terminal end, starting at amino acid 69 comprises a domain with homology to the C/C2 region of human coagulation factors V and VIII, a portion of which is shown in Table 1 above. The sequence contains four potential N-linked glycosylation sites, all present in the C1C2-like domain, numerous potential O-linked glycosylation sites, disulfide linkages,

and phosphorylation sites (protein kinase C and casein kinase II). The greatest homology to other proteins is seen with the 66/55 Kdalton antigen MFGE8 isolated from mouse milk fat globule (Stubbs et al., supra) as shown in Table 5 above and Table 6 below.

Table 6: Comparison of Deduced 46 Kdalton H M F G Antigen Sequence to other Protein Sequences

BA46C1	KCVEPLGMENGIANSQIAASSVRVT--FLGLQHWVPELARLNLRAGMVNA	
MFGE8C1	RCSTQLGHEGGAIADSQISASYVMG--FMGLQRWGPPELARLYRTGIVNA	
BA46C2	GCANPLGLQNSIPDKQITASSSYKTWGLHLFS-WNPSYARLDKQGNFNA	
MFGE8C2	GCLEPLGLKQNTIPDSQMSASSSYKTWNLRAFG-WYPHLGRLDNQKINA	
FA5C2	GCSTPLGMBNGKIENKQITASSPKKSW-WGDY--WBPFRARLNAQGRVNA	
FA8C2	SCSMPLGMBESKAI SDAQITASSYPTN---HPATWSPSKARLHLQGRSNA	
FA5C1	DCRMFMGLSTGIIISDSQIKASEP-----LGYWEPRLARLNNGGSYNA	
FA8C1	KCQTPLGMASGHIRDFQITASGQ-----YQWAPKLARLHYSGSINA	
A5C1	QCKRALGMBESGHIHPDQISVSSQYSM-----NWSAERSRLNY--VENG	
A5C2	PCSRMLGMVSGGLISDSQITASSQVDR-----NWVPELARLVT--SRSG	
DDRC1	KCRYALGMQDRTIPDSDISASS---SWS---DSTAARHSRLSSSDGDGA	
DISC		DGSEA
GP55	GCLEPL	WGPPELAR
BAND16		WAPPELAR

BA46C1	WT----PSSNDDNPWQVNLRLRMWVTGVVTQGA--SRLASHEYLKAPKV	
MFGE8C1	WH----ASNYDSLPIQVNLRLKMRVSGVMTQGA--SRAGRAEYLKTFKV	
BA46C2	WV----AGSYGNDQWLQVDLGSSKEVTGIIITQGA--RNFPGSVQFVASYKV	
MFGE8C2	WT----AQSNBAKEWLQVDLGTQRQVGTGIIITQGA--RDPGHIQYVESYKV	
FA5C2	WQ----AKANNKQWLEIDLLKIKKITAIIITQGC--KSLSSMYVKSYTI	
FA8C2	WR----PQVNNPKQWLQVDFQKTMKVTGVTITQGV--KSLTSMYVKBFLLI	
FA5C1	WSVEKLAABFASKPMIQVDMQKEVITIGITQGA--KHYLKSCTTTEFPYV	
FA8C1	WSTK---EPFS---WIKVDLLAPMIINGIKTQGA--RQKPSLYISQFTI	
A5C1	WT-PGSDT---VKQWIQVDLENLRFVSGIGYQGAISKETKCKYVVKSYKV	
A5C2	WALPPSNTHPYTKQWLQIDLAEEKIVRGVITIQGG--KHKENKVPMRKFKI	
DDRC1	WC-PAGSVFPKEBEYLQVDLQRLHLVALVGTQGRHAGGLGKE-PSRSYRL	
DISC	WC-----SSIVDTNQYIVAGCEVPRTFMCVALQGR-GDADQW---VTSYKI	
GP55		
BAND16		KMXVTXVVTQGA--SR

BA46C1	AYSLNGHEFD-FIHDVNTQGHKEFVGNNMKNQAVHVNLFETPVEAQYVRLYP	
MFGE8C1	AYSLDGRKFE-FIQDESGGDKFELGNLDNNSLKVNMPNPTLEABYIRLYP	
BA46C2	AYSNDSANWTEYQDPRTGSSKIFPGNWDNHSKQNLFPETPILARYVRILP	
MFGE8C2	AHSDDGQVQWTVYEBQ--GSSKVPQGNLDNNSHQQNIFKPPPMARKVRVLP	
FA5C2	HYSEQGVWKPYPRLKSSMVDKIFEGNTNTKGVKQNFNPPIISRPIRVIP	
FA8C2	SSSQDGHQWTLFPQN--GKVKVPQGNQDSPTPVNSLDPLLTLYRLIHP	
FA5C1	AYSSNQINWQIFKGNSTRNVMPNGNSDAITKENQDPPPIVARYIRIS	
FA8C1	MYSLDGKKQTYRGNSTGTLMPVPPGNVDSSGIKHNIFNPPIIARYIRLHP	
A5C1	DISSNGBDWITLKGKHL--VPTGNTDATDVYRPPSKPVITRFVRLRP	
A5C2	GYSNNGTEWBMIMDSSKQPKTFEGNTNYDTPELRTFAH-ITTFIKRIIP	
DDRC1	RYSRDGRRWGMGWKRWGQ--EVISGNEDEPGVVLKLGPPMVARLVRFYP	
DISC	RYSLDNVSWFBYRNGAA-----VTGVTDRTNVNHFDDTPIRARSIAIHP	
GP55		LNMFSAPLEVQYVR
BAND16		INLPDTPLETQYVR

Table 6: Comparison of Deduced 46 Kdalton H M F G
Antigen Sequence to other Protein Sequences (Cont'd)

BA46C1	TS-CHTACTLRPELLGCS---LN	(SEQ. ID No:10)
MFG8C1	VS-CHRGCTLRPELLGCS---LH	(SEQ. ID No:11)
BA46C2	VA-WHNRIALRLLELLGC-----	(SEQ. ID No:12)
MFG8C2	VS-WHNRIALRLLELLGC-----	(SEQ. ID No:13)
FA5C2	KT-WNQSITLRLELFGC---DIY	(SEQ. ID No:14)
FA8C2	QS-WVHQIALRMEVLGCBAQDLY	(SEQ. ID No:15)
FA5C1	TR-AYNRPTLRLELQGCENV--	(SEQ. ID No:16)
FA8C1	TH-YSIRSTLRMELMGCDLNS--	(SEQ. ID No:16)
A5C1	VT-WENGISLRPELYGCKI-TDY	(SEQ. ID No:17)
A5C2	ERASASGLALRLLELLGCEVETPT	(SEQ. ID No:18)
DDRC1	RADRVMSVCLRVELYGC-----	(SEQ. ID No:19)
DISC	LT-WNGHISLRCEFYTQ-	(SEQ. ID No:20)
GP55	FELLGCS---LNGCLEPL	(SEQ. ID No:21)
BAND16	VELLGC	(SEQ. ID No:22)

BA46C1:	Human 46 Kdalton Milk Fat Globule Polypeptide (Clone 1)	
BA46C2:	" " " " " " " " " " " "	(Clone 2)
MFG8C1:	Murine Milk Fat Globule Antigen Polypeptide (Clone 1)	
MFG8C2:	" " " " " " " " " " " "	(Clone 2)
FA5C1:	Coagulation Factor V	(Clone 1)
FA5C2:	" " V	(Clone 2)
FA8C1:	" " VIII	(Clone 1)
FA8C2:	" " VIII	(Clone 2)
A5C1:	A5 Protein	(Clone 1)
A5C2:	A5 Protein	(Clone 2)
DDRC1:	DDR Protein	(Clone 1)
DISC:	Discoidin Protein	
GP55:	Protein	
BAND16:	Protein	

The difference between the human 46 Kdalton polypeptide (BA46) and MFG-E8 is that the former has a single EGF-like sequence and lacks the proline rich region that is present between the second EGF-like sequence and the C1C2-like sequence of coagulation factors V and VIII in MFG-E8 (See, Table 6 above). The cell adhesion sequence RDG is also present in MFG-E8 but was not noted by the authors when published (Stubbs et al., supra), which is separated by the EGF-like sequence in both mouse and human proteins by 6 amino acids (See, Table 6 above). All cysteines in the human 46 Kdalton polypeptide are in identical positions compared to MFG-E8, two in the signal peptide, 3 preceding the RGD sequence, 3 in the EGF-like sequences, and 5 in the C/C2-like sequence. Both proteins have 4 N-linked glycosylation sites, but in the human 46 Kdalton polypeptide all are present in the C1C2-like sequence, while in MFG-E8, three are in the C1C2-like sequence and one after the first EGF-like sequence that is absent from the 46 Kdalton polypeptide. The second N-linked glycosylation site on the human 46 Kdalton polypeptide occurs in the same position as in MFG-E8.

The cell adhesion sequence (RGD) was originally found in fibronectin and shown to be crucial for interaction with its cell surface receptor, such as the integrins (Cherny

et al, J. Biol. Chem. 268:9725 (1993)). Other proteins containing this cell adhesion sequence (RGD) are fibrinogen, vitronectin, Von Willebrand coagulation factor, entactin, some isoforms of tumor growth factor beta, and slime mold discoidin I (Poole et al., "Sequence and expression of the discoidin I gene family in dictyostelium", J. Mol. Biol. 5 153:273-289 (1981)). The RGD sequence is also found on some collagens and on surface proteins of some animal viral proteins that serve the same cell adhesion purpose. Viruses whose surface proteins contain the RGD sequence include the coxsackie virus, the foot-and-mouth disease virus, the human immunodeficiency virus type 1 (HIV1), and certain flaviviruses such as Murray Valley encephalitis virus, the 10 Japanese encephalitis virus, the yellow fever virus, the West Nile virus Dengue type 4 virus, and the tick-borne encephalitis virus. The interaction of the cell adhesion sequence with its cell receptor is inhibited by synthetic peptides containing the RGD peptide.

The function of the EGF-like sequences is not known. However, this sequence 15 is present on a number of growth factors, proteins associated with cell interaction and adhesion, and developmental proteins. The growth factors include TGF-alpha, amphiregulin, and growth factor-related proteins of the vaccinia, myxoma, and Shope fibroma viruses. The EGF-like sequence is also present on coagulation associated proteins, complement components, fibronectin, selectins, and several Drosophila 20 developmental proteins such as the Notch-1, the neurogenic repetitive locus proteins, 95F and delta).

The C1C2 domain of human coagulation factors V and VIII has been shown to be involved in phospholipid binding, that is an essential property for the involvement of these factors in coagulation. The binding appears to be to phosphatidyl serine (Ortel 25 et al., "Deletion analysis of recombinant human factor V. Evidence for a phosphatidyl serine binding site in the second C-type domain", J. Biol. Chem. 267:4189-4198 (1992)). The 46 Kdalton polypeptide appears to be a member of a family of proteins that contain these C-type domains (See, Table 6). These include the mouse milk fat globule protein MFG-E8 (Stubbs et al., supra), a putative neuronal cell adhesion 30 molecule (A5 antigen) of *Xenopus laevis* (Takagi et al., "The A5 Antigen, a candidate for the neuronal recognition molecule, has homologies to complement components and coagulation factors", Neuron 7: 295-307 (1991)), a receptor tyrosine kinase found in human breast carcinoma (DDR), and discoidin I, an endogenous lectin of slime mold *Dictyostellum discoideum* (Poole et al., supra). The coagulation factors, BA46, MFG- 35 E8, and the A5 antigen have two C-type domains that apparently resulted from an earlier tandem duplication. Both DDR and discoidin I have single C-type domains and

appear to be primitive members of the family.

Example 21: Dendrogram of Protein Family

A dendrogram of the alignment of the C-type domains shown in Table 6 above was constructed and shows that this alignment likely occurred and split human protein
5 DDR and slime mold discoidin I from the other proteins with C and C2 domains. The dendrogram is shown in Figure 2 accompanying this patent.

A separation of the *Xenopus* A5 antigen from the other human coagulation factors and the mouse and human milk fat globule proteins appears to have occurred thereafter. Finally, the coagulation factors were later separated from the milk fat
10 globule proteins. The C1C2 domain appears to have evolved as a unit, since the C regions of BA46 and MFG-E8 have more homology than with their own C2 domains. This is also the case for the C and C2 domains of factors V and VIII (See, Table 6 above). In fact, the C2 domains of the coagulation factors are more homologous to the BA46 and MFG-E8 C2 domains than they are to the their own C domains. The
15 similarity also extends to the sequences of the peptides from the milk fat globule components of bovine (component 16) and guinea-pig (GP-55) (Mather et al., "The major fat-globule membrane proteins, bovine components 15/16 and guinea-pig GP 55, are homologous to MGF-E8, a murine glycoprotein containing epidermal growth factor-like and factor V/VIII-like sequences", *Biochem. Mol. Biol. Int.* 29: 545-554, 1993)).
20 (See, Table 6 above).

The C2 domain of the coagulation factors is critical for phospholipid binding. This is also most likely the case for the C2-like domains of the milk fat globule factors, including the 46 Kdalton HMFG polypeptide of the invention. The current evidence suggests that the MFG-E8 antigen binds to phospholipids, and that this binding is Ca^{++}
25 dependent (Buse et al, *J. Cell Biol.* 115:1969 (1991)). In contrast, the replacement of the C2 domain of factor V with the C2-like domain of the 46 Kdalton HMFG polypeptide was shown to abolish the phospholipid binding properties in the chimeric protein, while its replacement with the C2 domain of factor VIII did not (Ortel et al., "Epitope mapping of the C2 domain of coagulation factor V using antibodies and
30 chimeras with heterologous C-type domains" (1993)). In contrast to the phospholipid binding reported by Parry et al, supra, this binding is not Ca^{++} dependent.

These results permit the grouping of the 46 Kdalton HMFG polypeptide with growth factors and other molecules associated with cell adhesion/interactions, e.g. associated with breast epithelial cells, that provide a possible autocrine/paracrine
35 function. The 46 Kdalton HMFG antigen is thus related to selectin-like molecules (

Larigan, J.D., Tsang, T.C., Rumberger, J.M., and Burns, D.K., "Characterization of cDNA and genomic sequences encoding rabbit ELAM-1: Conservation of structure and functional interactions with leukocytes", *DNA Cell Biol.* 11:149-162 (1992)), which have the general structure of an N-terminal adhesion domain (lectin domain) followed by an EGF-like domain, a variable number of complement regulatory elements, a membrane attachment domain (a single transmembrane sequence) and a short cytoplasmic tail (Larigan, J.D., Tsang, T.C., Rumberger, J.M., and Burns, D.K., "Characterization of cDNA and genomic sequences encoding rabbit ELAM-1: conservation of structure and functional interactions with leukocytes", *DNA Cell Biol.* 11:149-162 (1992)). The C-type domain is very likely the means by which the 46 Kdalton HMFG polypeptide associates with the cell membrane by interaction with phospholipids. The possible cell adhesion properties may be mediated via the cell adhesion sequence RGD since breast cells are known to possess integrins that have receptors for this sequence. The autocrine may be mediated by the EGF-like sequence. The 46 Kdalton HMFG antigen is abundantly present in the HMFG and the expression of its mouse homologue is increased during lactation (Stubbs et al., supra). Thus, the expression of the human 46 Kdalton HMFG antigen and its mouse homologue appear to be associated with differentiation in the breast.

The overexpression of the 46 Kdalton antigen mRNA in some breast, lung and ovarian cancers such as carcinomas shows that the 46 Kdalton antigen is expressed with other epithelial tissues and may be deregulated in malignancy. Its expression in breast cancers such as carcinomas makes it a good target for monoclonal antibody therapy. Of the known monoclonal antibodies raised against the 46 Kdalton HMFG antigen, Mc3, which recognizes an epitope in the N-terminal region of the polypeptide, is more effective in radioimmunotherapy than Mc8, which recognizes an epitope in the C2-like domain of the 46 Kdalton polypeptide (unpublished results). This effectiveness of Mc3 in radioimmunotherapy is in all likelihood the result of an internalization of the antigen-antibody complex formed, which increases the residence time of the radiolabel in the tumor. In addition, the antibody is likely involved in modulating cell growth by interfering with the effect of the target antigen on growth regulation and cell association.

The anti-viral activity of the 46 Kdalton HMFG polypeptide appears to be mediated via binding of the antigen to the virus (Yolken et al., "Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis", *J. Clin. Invest.* 90: 1984-1991 (1992)). The desialylation of the 46 Kdalton HMFG polypeptide was shown to abolish its anti-viral activity (Yolken et al., supra.)

**Example 22: Bacterial Expression of Complete
46 Kdalton H M F G Antigen**

A recombinant polynucleotide and its polypeptide product encompassing the entire 46 Kdalton HMFG antigen were produced by cloning the BA46 cDNA segment
5 that codes for entire ORF except for the signal peptide obtained above. Poly A containing mRNA was isolated from a breast cell line (ELL-G) using the FastTrack mRNA isolation kit (Invitrogen, San Diego) according to the manufacturer's instructions. The mRNA was reversed transcribed and amplified using an upstream primer at the 3' end of the signal peptide encoding sequence and a downstream primer
10 at the first stop codon. Each primer was constructed to have a Hind III restriction enzyme site. The amplified sequence was then cut with the restriction enzymes Stu I and Apa I, which cut it into three fragments. These fragments were cloned into a pBS vector and sequenced to verified that no mutations were introduced by the PCR reactions. Once the identity of the sequence fragments was verified, the fragments
15 were ligated together and cloned into the pBR322/lacP/OmpA and pBS//OmpA expression vectors. The expression of the product in the vector was thus driven by the LacP promoter and and a bacterial signal peptide substituted for the BA46 signal peptide. Both vectors, when transfected into E. coli, expressed the 46 Kdalton HMFG antigen. The presence of the product was observed in the medium, periplasm, and
20 protoplast of the transfected E. coli. The authenticity and identity of the recombinant peptide produced was demonstrated by binding of all available anti-46 Kdalton HMFG antigen monoclonal antibodies, Mc3, Mc8, Mc15, Mc16, to the transfected E. coli extracts in a solid phase radioimmunobinding assay. All the monoclonal antibodies recognized epitopes on the peptide core of the 46 Kdalton HMFG antigen. No
25 monoclonal antibody bound to control bacteria extracts transfected with the same vectors but without the insert.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein.

CLAIMS

1. A purified, isolated polypeptide having the antibody binding specificity of the 46 Kdalton apparent molecular weight (app. MW) human milk fat globule (HMFG) antigen and/or homology to at least a portion of one of the light chains of clotting factors V and VIII and/or comprising an RGD and/or EGF-like segment.
2. The polypeptide of claim 1, being the 46 Kdalton HMFG app. MW antigen or a binding fragment thereof.
3. The polypeptide of claim 1, having the biological activity of the 46 Kdalton HMFG antigen.
4. The polypeptide of claim 1, having an estimated MW of about 43,123 or about 387 amino acids.
5. The polypeptide of claim 1, having an estimated MW of about 40,862 or about 365 amino acids.
6. The polypeptide of claim 1, having the amino acid sequence shown in Table 4 (SEQ. ID No: 6) or a binding fragment thereof of about 5 to 100 amino acids.
7. The polypeptide of claim 6, having the amino acid sequence shown in Table 2 (SEQ. ID NO: 3) or a binding fragment thereof of about 5 to 100 amino acids.
8. The polypeptide of claim 1, in glycosylated form.
9. A composition comprising an antibody binding effective amount of the polypeptide of claim 1, and a biologically acceptable carrier.
10. A pharmaceutically composition comprising the composition of claim 9, wherein the carrier comprises a pharmaceutically-acceptable carrier.
11. A fusion protein, comprising the polypeptide of claim 1, and a second polypeptide or a binding fragment thereof bound thereto.
12. A composition comprising the fusion protein of claim 11, and a diluent or biologically acceptable carrier.
13. The pharmaceutical composition of claim 12, wherein the carrier comprises a pharmaceutically-acceptable carrier.
14. An in vitro assay for detecting the presence in a biological sample of the 46 Kdalton HMFG antigen or fragments thereof, comprising obtaining a biological sample suspected of comprising the antigen or a fragment thereof; adding thereto an antibody selectively binding the antigen and a known labeled amount of the polypeptide of claim 1 under conditions effective to form antibody-polypeptide and antibody-antigen complexes; determining the amount of labeled antibody-polypeptide complex formed;

and comparing the result with a control conducted without the sample.

15. An in vitro assay for determining the presence of a cancerous tumor of epithelial origin, comprising obtaining a biological sample from a subject suspected of being afflicted with a cancer of epithelial origin; adding thereto an antibody selectively binding the 46 Kdalton app. MW HMFG antigen and a known labeled amount of the polypeptide of claim 1 under conditions effective to form labeled antibody-polypeptide and antibody-cell antigen complexes; determining the amount of labeled complex formed; and comparing the result to a control without the sample.

16. The composition of claim 42 in a form suitable for imaging neoplastic tumors of epithelial origin, comprising the anti-46 Kdalton HMFG antigen antibodythe antibody in an amount effective to deliver it to the area of a subject's body containing malignant tumor cells of epithelial origin to form an antibody-cell polypeptide complex, which can be detected by addition of a label capable of binding to the antibody at a site other than the polypeptide.

17. The composition of claim 10, comprising an amount of the polypeptide effective to elicit an immunologic response suitable for vaccination against neoplastic tumors of epithelial origin.

18. An in vitro assay for diagnosing the presence of a neoplastic tumor of epithelial origin, comprising obtaining a sample from a subject suspected of being afflicted with a neoplastic tumor of epithelial origin; adding thereto the polypeptide of claim 1 under conditions effective to form antibody-46 Kd HMFG antigen and antibody-antigen fragment complexes; and determining the presence of any complexes formed.

19. An in vitro assay for diagnosing a neoplastic tumor of epithelial origin, comprising obtaining a sample from a subject suspected of being afflicted with a neoplastic tumor; adding thereto an the fusion protein of claim 10 under conditions effective to form an antibody-fusion protein complex; adding thereto the anti-second polypeptide antibody under conditions effective to form a double antibody-fusion protein complex; and determining the presence of any double antibody-fusion protein complex formed.

20. A composition suitable for administration to a subject suspected of carrying a neoplastic tumor of epithelial origin to deliver a therapeutic agent to target tumor cells of epithelial origin, comprising a therapeutically effective amount of a therapeutic agent bound to the antibody of claim 41 at a site other than the antigen binding site under conditions effective for the antibody to bind to the tumor cells' polypeptide and allow the therapeutic agent to exert its effect on the cells.

21. An ex vivo method of delivering a therapeutic agent to target neoplastic tumor cells, comprising obtaining a biological sample from a subject suspected of being afflicted with a neoplastic tumor of epithelial origin; binding a therapeutic agent to the antibody of claim 41 at a site other than the antigen binding site; adding the antibody-bound therapeutic agent to the sample under conditions effective to promote the formation of an antibody-cell polypeptide complex; allowing the agent to exert its effect on the cells; and returning the sample to the subject.

22. The composition of claim 10 in a form suitable for vaccination of mammals against neoplastic tumors, comprising an antigenically effective amount of the polypeptide.

23. A polyribonucleotide comprising an oligoribonucleotide encoding the polypeptide of claim 1 or 5 to 100 amino acid fragments thereof.

24. A polydeoxynucleotide comprising a DNA segment having a nucleotide sequence complementary to that of the polyribonucleotide of claim 23.

25. The polyribonucleotide of claim 23, being a polydeoxyribonucleotide comprising the DNA sequence shown in Table 4 (SEQ. ID No: 7) or fragments thereof encoding 5 to 100 amino acids thereof.

26. The polyribonucleotide of claim 25, having the DNA sequence shown in Table 1 (SEQ. No. 1) or fragments thereof encoding fragments 5 to 100 amino acids thereof.

27. The polyribonucleotide of claim 23, in labeled form.

28. The polyribonucleotide of claim 25, being an RNA.

29. The polydeoxyribonucleotide of claim 28 in labeled form.

30. A polyribonucleotide comprising an oligoribonucleotide encoding the fusion protein of claim 11.

31. An in vitro assay for diagnosing a neoplastic tumor of epithelial origin, comprising obtaining a biological sample from a subject suspected of being afflicted with a neoplastic tumor of epithelial origin; lysing any cells comprised in the sample to expose polynucleotides contained therein; adding thereto the polynucleotide of claim 24 in single stranded form under stringent conditions to hybridize any polynucleotides having a complementary sequence thereto of about at least 15 bases; and detecting the presence of any polynucleotide-DNA hybrid.

32. An in vitro assay for diagnosing a neoplastic tumor of epithelial origin, comprising obtaining a sample from a subject suspected of being afflicted with a neoplastic tumor of epithelial origin; lysing any cells comprised in the sample to expose polynucleotides contained therein; adding thereto the polynucleotide of claim

30, in DNA labeled form, under stringent conditions to hybridize any polynucleotides having a complementary sequence thereto of at least about 15 bases; and detecting the presence of the polynucleotide-DNA hybrid.

33. A DNA segment comprising an anti-sense sequence to the coding strand of the polyribonucleotide of claim 23 of about 15 to 3000 nucleotides.

34. A pharmaceutical composition, comprising the anti-sense DNA sequence of claim 33, and a pharmaceutically-acceptable carrier.

35. The composition of claim 34 comprising a therapeutically effective amount of the anti-sense DNA segment, for treating a neoplastic tumor of epithelial origin.

36. The composition of claim 35, for administration by a parenteral, intravenous, or intracavitary or other localized route.

37. An antibody detecting kit comprising, in separate containers, the polypeptide of claim 1; anti-constant region immunoglobulin, protein G or A or binding fragments thereof; and instructions for its use.

38. The kit of claim 37, further comprising anti-46 Kdalton HMFG antigen antibody or fragments thereof.

39. A fusion protein kit comprising, in separate containers, the fusion protein of claim 11; anti-46 Kdalton HMFG antigen monoclonal antibody; anti-second polypeptide monoclonal antibody; anti-constant region immunoglobulin, protein G or A or binding fragments thereof; and instructions for its use.

40. Antibody raised against, and selectively binding, the 46 Kdalton app. MW HMFG antigen, the antibody having an affinity constant for the antigen of about 10^{10} to 10^5 M^{-1} .

41. The antibody of claim 40, being a monoclonal antibody.

42. A composition, comprising the antibody of claim 40, and a non-proteolytic carrier.

43. An anti-cancer therapeutic kit, comprising, in separate containers, the monoclonal antibody of claim 40; an anti-cancer therapeutic agent selected from the group consisting of immunotoxins and radionucleides, which agent is bound to the antibody; and instructions for use of the kit.

44. A specifically targeted anti-cancer agent, comprising the antibody of claim 40, and an anti-cancer agent operatively linked thereto.

45. An anti-cancer kit, comprising the specifically targeted anti-cancer agent of claim 44; and instructions for its use.




FIGURE 1




FIGURE 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13967

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/277.1; 435/7.1, 69.3; 530/350, 387.7, 388.15, 828; 536/23.4, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, EMBASE, DERWENT
search terms: HMFG, antigen, 46 Kd

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	Proceedings of the National Academy of Sciences USA, Volume 79, issued September 1982, R.L. Ceriani et al., "Circulating Human Mammary Epithelial Antigens in Breast Cancer", pages 5420-5424, especially page 5420.	16, 20-21, 40-42 ----- 43-45
X -- Y	Cancer Research, Volume 51, issued 15 September 1991, D. Larocca et al., "A M, 46,000 Human Milk Fat Globule Protein that is Highly Expressed in Human Breast Tumors Contains Factor VIII-Like Domains", pages 4994-4998, see entire document.	23, 24, 27 ----- 1-3, 8-22, 30-45

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

08 MARCH 1995

Date of mailing of the international search report

16 MAR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL S. TUSCAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13967

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Analytical Biochemistry, Volume 201, Number 1, issued 15 January 1992, R.L. Ceriani et al., "A Novel Serum Assay for Breast Epithelial Antigen Using a Fusion Protein", pages 178-184, see entire document.	13-16, 30, 32, 39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13967

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 4-7, 25, 26, 28 and 29
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

no computer readable form of the disclosed sequences was provided. Without a computer readable sequence listing for the claimed DNA, no electronic search of the available sequence data bases could be performed.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/13967

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 35/20, 35/55, 39/00, 39/395; G01N 33/53; C07K 14/435, 16/18, 16/30; C12N 15/12, 15/62

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/277.1; 435/7.1, 69.3; 530/350, 387.7, 388.15, 828; 536/23.4, 23.5